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Traditional medicine in South Africa is part of the culture of the people and has been 
in existence for a long-time. Although animal components form part of the 
ingredients used, plant material constitutes the major component. South Africa is 
endowed with vast resources of medicinal and aromatic plants which have been 
employed for treatment against various diseases for decades. A large number of 
South Africans still depend on traditional medicine for their healthcare needs due to 
its affordability, accessibility and cultural importance. Helminth infections are among 
the variety of diseases treated by traditional healers. These infections are regarded 
as neglected tropical diseases (NTDs) due to their high prevalence among the 
economically disadvantaged living in rural areas in different regions of the world. 
 
For this study, eleven plants from nine families were selected based on their 
ethnopharmacological uses as anthelmintics. To validate the efficacy of the plants 
and for possible discovery of bioactive chemicals, it was deemed important to 
pharmacologically investigate the selected plants. Besides anthelmintic testing, 
antimicrobial activity and cyclooxygenase (COX) inhibitory activity screening of the 
plants were also carried out because microbial infections and inflammation are often 
associated with helminth infections. The plants investigated were also subjected to 
phytochemical analysis to test for the presence of different secondary metabolites 
that could be responsible for the biological activities observed. 
 
The plant materials were collected in KwaZulu-Natal between February and April 
2009. Plant parts used in traditional medicine were collected and for sustainable 
harvesting of medicinal plants in order to enhance conservation, alternative plant 
parts (leaves and twigs) of some of the plants were also investigated. Independently, 
the plant material was extracted using petroleum ether (PE), dichloromethane 
(DCM), ethanol (EtOH) and water. A total of 80 extracts were prepared from the 
selected plants which were screened for anthelmintic, antimicrobial and COX 
inhibitory activities. For the phytochemical analysis, 50% aqueous methanol (MeOH) 
extracts were used to determine the presence of phenolics and alkaloids, while water 
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extracts were used in the detection of saponins. Acetone extracts were used for the 
comparison of chemical „fingerprints‟ on thin layer chromatography (TLC) plates. 
 
For the in vitro anthelmintic screening, the free living nematode Caenorhabditis 
elegans var. Bristol (N2), which is morphological similar to parasitic nematodes, was 
used to evaluate the anthelmintic potential of the extracts. A modified microtitre plate 
technique, with the use of a viability indicator compound 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide-formazan (MTT-formazan), was used to determine 
the minimum lethal concentration (MLC) values of the extracts against C. elegans. 
The DCM extract of Hypoxis colchicifolia leaves showed the best MLC value of  
0.13 mg/ml. Besides H. hemerocallidea extracts, at least one of the extracts from 
other plant species investigated also exhibited high anthelmintic activity. Generally, 
ethanol extracts were the most active while water extracts displayed low or no 
anthelmintic activity in the bioassay. 
 
The test organisms used for the in vitro antimicrobial investigation were  
Gram-positive bacteria (Bacillus subtilis American type culture collection (ATCC) 
6051 and Staphylococcus aureus ATCC 12600), Gram-negative bacteria 
(Escherichia coli ATCC 11775 and Klebsiella pneumoniae ATCC 13883) and the 
fungus Candida albicans ATCC 10231. The microplate dilution technique was used 
to evaluate the minimum inhibitory concentration (MIC) of the plant extracts against 
the test organisms. In addition, the minimum fungicidal concentration (MFC) of the 
extracts was evaluated against the C. albicans culture. A total of 25 (31.3%) plant 
extracts exhibited noteworthy antibacterial activity and S. aureus was the most 
susceptible bacterium. PE and DCM extracts from the leaves of Leucosidea sericea 
had the best antibacterial activity against B. subtilis and S. aureus with an MIC value 
of 0.025 mg/ml. Although poor antifungal activity was displayed by most plant 
extracts, the PE extract of H. colchicifolia leaves exhibited both fungistatic (MIC: 0.78 
mg/ml) and fungicidal (MFC: 0.78 mg/ml) activity. Also, the water extract of Ocimum 
basilicum leaves had an MIC value of 0.78 mg/ml. 
 
COX-1 and -2 enzymes were used to determine the anti-inflammatory potentials of 
the plant extracts. Initially, the organic solvent and water extracts were tested at a 
final concentration of 250 µg/ml and 2 mg/ml, respectively. Many of the plant extracts 
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had higher inhibitory activity against COX-1 than the COX-2 enzyme. The DCM 
extracts of Acokanthera oppositifolia leaves and Felicia erigeroides stems exhibited 
the best COX-1 and COX-2 inhibition, respectively. As a result of the fewer side 
effects associated with COX-2 inhibition, it is preferred to COX-1 inhibition.  
Of the extracts tested, 32 showed COX-2 inhibition above 70% and were further 
evaluated at two lower concentrations (organic solvent extracts: 125 and  
62.5 µg/ml; water extracts: 1 and 0.5 mg/ml). Both COX-1 and -2 inhibition of these 
extracts were determined. Apart from the DCM extract of Senna petersiana leaves 
and the EtOH extract of O. basilicum leaves, that exhibited approximately the same 
level of inhibition at the three different concentrations tested, the other 30 extracts 
displayed a dose-dependent COX inhibition. 
 
Phytochemical analysis using spectrophotometric methods revealed the presence of 
phenolics including flavonoids, condensed and hydrolysable tannins at varying 
amounts in the plant extracts. Condensed tannins were not detected in the extracts 
of F. erigeroides stems and Cotyledon orbiculata var. dactylopsis leaves.  
A qualitative test for saponins was positive for the extracts of A. oppositifolia twigs, 
Clerodendrum myricoides stems, Cyathea dregei leaves and roots, F. erigeroides 
leaves and stems, Hypoxis species corms and L. sericea stems while alkaloids were 
only detected in leaf extracts of A. oppositifolia, C. orbiculata var. orbiculata, Hypoxis 
species and L. sericea. TLC fingerprinting of acetone extracts allowed for the 
visualization of the compounds present in the plant extracts. The leaf extracts were 
shown to contain more compounds than the other plant part extracts, as would be 
expected. 
 
The screening of the plants for pharmacological activity and phytochemical 
compositions provided valuable preliminary information validating the use of some of 
the plants in the traditional medicine. In addition, this study has further confirmed the 
need to screen medicinal plants for other pharmacological activities related to the 
diseases for which the plant is traditionally used. Many of the plants investigated 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 Plant medicinal value 
 
The relationship existing between plants and humans is as old as mankind, dating 
back to the origin of human civilization (RATES, 2001). Humans have relied on 
plants for food, clothing, shelter, fuel and medicine (NEWMAN et al., 2000). Plants 
continue to be an integral part of human existence, making ethnobotany an 
interesting and important research field (SUMNER, 2000; OKUJAGU et al., 2006). 
GURIB-FAKIM (2006) has identified plants as forming the basis of a sophisticated 
traditional medicine from antiquity to date. Most medicinal plants were used against 
ailments such as coughs, colds, parasitic infections and inflammation; probably 
based on trial and error. This ancient Knowledge was verbally transferred from one 
generation to another (GURIB-FAKIM, 2006; OKIGBO et al., 2008). Therapeutic 
plant use can be a herbal tea, a crude extract, a phytopharmaceutical or herbal 
mixture or isolated compounds (RATES, 2001). 
 
Globally, many pharmacological and economically noteworthy medicinal plant 
species have had multiple uses (AJIBESIN et al., 2008). The variation in African 
traditional medicine is due to rich biological and cultural diversity on the continent 
(GURIB-FAKIM, 2006). Medicinal plants are found and frequently used in China, 
India, Japan, Pakistan, Thailand and particularly to this study, in South Africa 
(MUKHTAR et al., 2008). Globally, the Indian Ayurvedic and Chinese traditional 
medicine are recognized as the oldest and most developed respectively (GURIB-
FAKIM, 2006). Traditional medicine also exists in southern America and Australia, 
but these are not as developed as in Asia or Africa. Distinct traditional medicinal 
systems are found universally in each geographical region, so that medicinal plant 
use is diverse globally (AJIBESIN et al., 2008). 
 
1.2 Traditional medicine in South Africa 
 
The World Health Organization (WHO) defined traditional medicine as “the health 
practices, approaches, knowledge and beliefs incorporating plant, animal and 
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mineral based medicines, spiritual therapies, manual techniques and exercises, 
applied singularly or in combination to treat, diagnose and prevent illnesses or 
maintain well being” (WHO, 2008). Plant and animal-based, traditional medicine 
provide holistic treatments as opposed to the chemical-based, scientific western 
medicinal treatment providing cause and effect units. In a holistic approach, factors 
such as individual mental, social, spiritual, physical, and ecological states are 
considered in addressing the symptoms, causes and cures for an ailment 
(CUNNINGHAM, 1993; BODEKER, 2004). CUNNINGHAM (1997) studied different 
African ethnobotanical systems and established that plants are the main ingredients 
used in most traditional medicines. 
 
Traditional medicine has been in existence for a long-time and forms an integral part 
of the culture of many South Africans (VAN STADEN, 2008). VAN WYK et al. 
(1997) highlighted approximately 3000 plant species that are used for medicinal 
purpose by an estimated 200 000 indigenous traditional South African healers. The 
country is regarded as having one of the most diverse temperate floras in the world 
due to its abundant and rich floral biodiversity, with an estimated 24 000 plant taxa 
(LOW and REBELO, 1996; VAN STADEN, 2008). South Africa, like most 
developing countries, has traditional medicine as an informal alternative to the rural 
healthcare system due to shortage of Western-trained medical doctors, inadequate 
healthcare facilities and medical equipment in most rural areas (VAN WYK et al., 
1997; LIGHT et al., 2005). In the urban areas, a large proportion of the black 
population patronise traditional medicinal healers in addition to the western-trained 
doctors (MANDER et al., 2007). 
 
An estimated 27 million South Africans depend on traditional medicine because of its 
presumed affordability, availability and cultural importance (MANDER, 1998). 
Research findings by MANDER (1998) revealed a diverse range in users of 
medicinal plants, indicating that educational level, occupation, age, and religion were 
not determining factors for medicinal plants use. This observed diversity in medicinal 
plant users was also found in other African countries such as Ethiopia (MANDER et 
al., 2007). The increase in patronage of traditional medicine by South Africans has 
been linked to the escalating HIV/AIDS epidemic and other common infectious 
diseases (MANDER, 1997). Unfortunately, South Africa, like most African countries, 
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is gradually losing this rich traditional knowledge due to lack of proper documentation 
of medicinal knowledge (LIGHT et al., 2005). 
 
South Africa has experienced an increase in ethnopharmacology research due to 
increased government financial support and researchers‟ recognition of the 
economic value of available botanicals (LIGHT et al., 2005; VAN VUUREN, 2008). 
Many workers have reported ethnobotanical usage of plants as medicines in various 
provinces such as KwaZulu-Natal (HUTCHINGS et al., 1996), Western Cape 
(THRING and WEITZ, 2006), and Eastern Cape (BHAT and JACOBS, 1995) 
Provinces. This has resulted in the investigation of many South African plants for 
bioactivities such as antibacterial (KELMANSON et al., 2000), antifungal (MASOKO 
et al., 2007), anti-inflammatory (IWALEWA et al., 2007), and anthelmintic (McGAW 
et al., 2000) activities. These works were aimed at validating and isolating of 
bioactive compounds from the investigated plants. Interestingly, most of the 
screened plants were found to be effective, validating traditional usage as medicines 
by many South Africans. Also, a number of bioactive compounds have been isolated 
from South African plants (VAN VUUREN, 2008). 
 
Some popular and widely used South African medicinal plant species include 
Agathosma betulina (Buchu), Aloe ferox (Cape aloe), Harpagophytum procumbens 
(Devil‟s claw), Siphonochilus aethiopicus (African wild ginger) and Hypoxis 
hemerocallidea (African potato) (VAN WYK et al., 1997). Presently, most herbal 
preparations containing some of these species are well packaged and available in 
most traditional health shops in the country. 
 
The South African government has proposed the integration of traditional medicine 
into the national healthcare system but a number of problems that might hinder the 
plan have been identified (GQALENI et al., 2007 ). For instance, JÄGER (2005) 
raised concerns on the low number of research projects dealing with diseases 
affecting the majority of the population who are the main users of traditional 
medicine. Some of these diseases include diarrhoea, malaria, schistosomiasis, 
leishmaniasis and helminthiasis. Furthermore, the lack of regulation in the 
prescription, usages of traditional medicines and the need for proper toxicological 
tests to determine its safety has been recommended (FENNELL et al., 2004).         
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In view of this, BODEKER (2004) suggested the need for national governments to 
encourage more research into traditional medicinal plants and emphasized the 
importance of developing good policies, regulations and trade standards due to the 
increase in number of people that currently depend on traditional medicine as the 
sole source of their primary healthcare. 
 
1.3 Drug discovery from medicinal plants 
 
RATES (2001) defined a drug as “a pharmacologically active compound, which is a 
component of a medicine, irrespective of its natural, biotechnological or synthetic 
origin”. It is used in the treatment, cure, prevention or diagnosis of diseases. 
According to WHO (1998), “a medicine is a product prepared according to legal and 
technical procedures, which is used for the diagnosis, prevention and treatment of 
disease and has been scientifically characterized in terms of its efficacy, safety and 
quality”. Many methods have been used in obtaining compounds for drug production, 
these include isolation from plants and other natural sources like microbes, synthetic 
chemistry, combinatorial chemistry and molecular modelling (BALUNAS and 
KINGHORN, 2005). There are challenges associated with each method, 
necessitating the need for one method to complement the other (SHU, 1998). 
 
Natural product sources such as plants and animals have been utilized as drugs for 
centuries, with a deep attachment to the socio-cultural life of early humans (RATES, 
2001). The isolation of morphine from opium (Papaver somniferum) by the German 
pharmacist Friedrich Sertϋrner in 1805 marked the beginning of isolation of pure 
compounds from plants (KINGHORN, 2001). This development led to the isolation of 
drugs such as cocaine (Erythroxylum coca), codeine (Papaver somniferum), digitoxin 
(Digitalis species) and quinine (Cinochona species), with the majority still in use 
(NEWMAN et al., 2000; BUTLER, 2004). The importance of plants as one of the 
natural sources of drugs cannot be over-emphasized as about 25% of the drugs 
prescribed worldwide come from plants (RATES, 2001). NEWMAN et al. (2003) 
researched 55 categorized human diseases (such as cancer, microbial and parasitic 
infections) and found that 87% of the medications in use were derived from natural 
products from plants. 
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There are many challenges encountered in the drug discovery process, some of 
these include the high cost involved, which has been estimated to be over US$ 800 
million, the long period of time required for the process (minimum of 10 years), and 
the low average yield of isolated compounds from natural products which are mostly 
insufficient for lead optimization, development and clinical trials (REICHERT, 2003; 
DICKSON and GAGNON, 2004; BALUNAS and KINGHORN, 2005). This process 
of drug discovery is also characterized by a very low chance of success as it has 
been estimated that only one in 5000 lead compounds will successfully advance 
through clinical trials for final approval as a drug (BALUNAS and KINGHORN, 
2005). 
 
Despite the challenges and obstacles encountered in drug discovery from plants, a 
number of clinically useful isolated bioactive compounds from natural products are 
currently in use and many are also being investigated (NEWMAN et al., 2003; 
BALUNAS and KINGHORN, 2005). For this reason, natural products isolated from 
plants have been predicted to continue to remain an essential part of the search for 
novel medicines against human diseases (NEWMAN et al., 2000; BALUNAS and 
KINGHORN, 2005). To achieve significant success, BUTLER (2004) emphasized 
the need for all concerned scientists to develop faster and better techniques for plant 
collection, crude extract preparation, bioassay screening, compound(s) isolation and 
development to keep pace with other drug discovery efforts. There is a bright future 
for the discovery and development of more drugs from plants due to the large 
number of plant species that have not been pharmacologically and phytochemically 
investigated (SUMNER, 2000; GURIB-FAKIM, 2006). The use of medicinal plants 
will continue to play an important role as an effective health aid, especially for the 
large number of poor people in the third world and developing countries. 
 
1.4 Economic benefits of medicinal plants 
 
According to WHO (2008), 80% of the population in some Asian and African 
countries depend on traditional medicine for primary healthcare. In the last two 
decades, the developed and developing countries have witnessed a significant rise 
in the demand for herbal medicines with global sales estimated at US$ 60 billion 
(HOAREAU and DaSILVA, 1999; WHO, 2003). Herbal treatment has become 
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lucrative in the international market generating US$ 14 billion for China in 2005 and 
US$ 160 million for Brazil in 2007. In addition, countries like Germany, Japan and 
Turkey have contributed significantly to the economic boom in the phytomedical 
market (LANGE, 1998; LAIRD et al., 2003; COSKUN and GENÇLER ÖZKAN, 
2005). 
 
In southern Africa, an estimated 700 000 tonnes of plant material valued at US$ 150 
million is consumed annually (WIERSUM et al., 2006). In South Africa, an estimated 
20 000 tonnes of plant material derived from around 700 different plant species, and 
valued at US$ 60 million (R 270 million) is traded annually (MANDER, 1998). 
MANDER et al. (2007) reported an estimated 133 000 income earning opportunities 
generated by the traditional medicinal plant trade sector which was comparable to 
5.6% of South Africa National Health budget. Rural people, especially women, are 
the major players involved in the harvesting, trading and serving as the traditional 
healers in this informal sector of the economy of South Africa (MANDER, 1998; 
WIERSUM et al., 2006). 
 
In KwaZulu-Natal, which is well known for its rich indigenous traditional knowledge 
system, the trade in ethnomedicinal plants was estimated to be worth US$ 10 million 
(R 60 million) and between 20 000 to 30 000 people derive an income from the trade 
of medicinal plant materials annually (MANDER, 1998). The actual economic value 
of the medicinal plant trade may be higher than estimated by the different 
researchers because the market is informal and the volume of sales are not easily 
quantified due to lack of records and the often illicit nature of the trade (BOTHA et 
al., 2004). 
 
Apart from KwaZulu-Natal, with probably the highest volume of trade, the trade of 
medicinal plants seems to cut across most of the provinces in South Africa as 
evidenced from various works in other provinces such as the Eastern Cape (DOLD 
and COCKS, 2002), Mpumalanga (MANDER et al., 2007; GQALENI et al., 2007), 
and Gauteng (BOTHA et al., 2004). These studies confirm the increases in the trade 
of medicinal plants locally, regionally and internationally (MARSHALL, 1998). 
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1.5 Conservation of medicinal plants 
 
OKIGBO et al. (2008) summarized conservation as “a process involved in the 
preservation and careful management of the environment as well as natural 
resources to prevent neglect, over-exploitation and destruction”. Most natural 
resources especially medicinal plants, are under strain due to increasing 
urbanization and increased demand by the population (ZSCHOCKE et al., 2000; 
OKIGBO et al., 2008). Globally, the demand for medicinal plants is increasing 
leading to over-exploitation and indiscriminate harvesting of the natural flora within 
all ecosystems (CUNNINGHAM, 1997). JÄGER and VAN STADEN (2000) identified 
the increased use of the non-renewable plant materials such as roots, bulbs and 
bark as the major contributing factor to the decline of most species in the wild. 
Furthermore, herbalists believe that the most potent principles are located in the 
underground plant parts, encouraging non-sustainable harvesting from the wild 
(SHALE et al., 1999). This problem is more pronounced in Africa considering that of 
the estimated 650 million hectares of closed forest areas, a loss of 1% is recorded 
annually (OKIGBO et al., 2008). MPIANA et al. (2007) emphasized the danger of 
the possible loss of the rich biodiversity of these ecosystems. Extinction of these 
plants before being investigated could cause an irreplaceable loss to future 
generations apart from the loss of benefits derived from such plants presently. 
 
In South Africa, various workers (VAN WYK et al., 1997; ZSCHOCKE et al., 2000; 
DOLD and COCKS, 2002) have highlighted the rise in forest depletion due to the 
increase in the demand for medicinal plants by a rapidly growing population coupled 
with the non-sustainable and indiscriminate harvesting of these medicinal plants from 
the wild. Popular species such as Warburgia salutaris and Siphonochilus aethiopicus 
are apparently extinct locally and available only in highly protected areas (MANDER, 
1998). There is a correlation between over-exploitation and indiscriminate harvesting 
by a high number of untrained gatherers. This group consists mostly of unemployed 
persons who lack experience in plant material collection but are involved in the trade 
for the immediate economic gains (MANDER et al., 2007). 
 
South Africa has a low success rate in the use of law enforcement for biodiversity 
conservation (WIERSUM et al., 2006). New approaches such as plant part 
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substitution as means for sustainable harvesting (ZSCHOCKE et al., 2000) and 
stimulation of medicinal plant cultivation have been recommended (VAN STADEN, 
1999; WIERSUM et al., 2006). For example, the non-destructive part of medicinal 
plants particularly the leaves should be investigated for possible bioactivity. 
Furthermore, traditional healers should be encouraged to use related plant species 
where similar biological activity has been demonstrated (ZSCHOCKE et al., 2000). 
This would reduce pressure on the popular threatened species and neccessiated the 
investigation of alternative plant parts in this study. Also, community based medicinal 
plant farming coupled with the provision of subsidy and basic techniques provided by 
government agencies would enhance conservation of medicinal plants. The 
domestication of medicinal plants will create new opportunities such as 
alternative/additional sources of income and help reduce the pressure on the wild 
natural medicinal plant population (JÄGER and VAN STADEN, 2000). 
 
1.6 Helminth infections  
 
Helminths are divided into three groups based on their body segmentations, namely: 
trematodes (flukes), nematodes (roundworms) and cestodes (tapeworms). Helminths 
have multi-cellular bodies and complex life cycles involving maturation in a host 
organism. Required nutrients are derived from the host, causing the parasitic activity 
of most helminths. Helminth infections are one of the most prevalent diseases in 
developing and developed countries (KROGSTAD and ENGLEBERG, 1998). 
Globally, an estimated 2 billion people are infected by intestinal nematodes (WEN et 
al., 2008). The increase in helminth infection and their growing resistance to most 
broad spectrum chemotherapeutics is a major problem facing human health  
(JAMES and DAVEY, 2009). Also infections by gastrointestinal helminth parasites in 
livestock is one of the most common and economically important diseases of grazing 
livestock (PERRY et al., 2002). In addition, research on development of new 
treatment regimes against helminth infections has been relegated to the background 
by the western governments, researchers and the pharmaceutical industries due to 
poor economic prospects and the presumed low priority of the diseases that go with 
it (GEARY et al., 1999a; GILLES and HOFFMAN, 2002). 
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Helminth infections resulting to diseases such as ascariasis, hookworm infection and 
schistosomiasis constitute the bulk of the 13 diseases classified as neglected tropical 
diseases (NTDs) by the WHO (HOTEZ et al., 2007a). These incapacitating diseases 
have continued to inflict severe disability and often death. It is more pronounced 
among the impoverished population living in marginalized areas of the world. HOTEZ 
et al. (2007b) estimated that the global burden of helminth infections, in terms of 
disability-adjusted life years (DALYs), is 39 million life years which was comparable 
to that of tuberculosis (34.7 million DALYs) or malaria (46.5 million DALYs), the two 
major human infectious diseases associated with an high mortality rate. 
 
In most developing countries, intestinal helminth infections are a major health 
concern because factors that pre-dispose humans to these infections abound in 
these areas (IJAGBONE and OLAGUNJU, 2006). Factors that sustain the parasite 
life cycles and favour the proliferation of the disease vectors include poor sanitation, 
poverty, unsafe water, malnutrition and ignorance (BROOKER et al., 2006a).  
As a result, parasitic diseases generally have become indices of low levels of  
socio-economic status of the countries where the infections are prevalent.  
Children, especially those at a preschool age (less than five years), have been 
identified as the most vulnerable group with very high rates of infection (SINNIAH, 
1984; De SILVA et al., 2003). Due to the asymptomatic nature of these diseases, 
they could remain undetected and children born in an endemic region may harbour 
the worms for the most part of their lives (WHO, 1987). 
 
South Africa has no reported official data on prevalence and intensity of helminth 
infections in the country as a whole (SCHUTTE et al., 1995; FINCHAM et al., 1996), 
but various workers have reported a high prevalence of intestinal nematode infection 
in Mpumalanga (EVANS et al., 1987), the Western Cape (FINCHAM et al., 1996) 
and KwaZulu-Natal (KVALSVIG et al., 1991; APPLETON et al., 1999; MABASO et 
al., 2004). Of particular interest is KwaZulu-Natal, the third poorest province in South 
Africa, which has a high mortality and prevalence of HIV/AIDS (HIRSCHOWITZ and 
ORKIN, 1997; MASLAN, 2001). The transmission and epidemiology problems of 
helminth infections have remained relatively high over a long period of time 
(JINABHAI et al., 2001), and children have continued to be the most vulnerable 
group in KwaZulu-Natal (TAYLOR et al., 1995; SAATHOFF et al., 2004). 
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The manifestation of most parasitic diseases is not only due to mechanical or 
chemical tissue damage but also the host responses to the presence of the parasite 
(MURRAY et al., 1998). Helminths consume nutrients from their host, thereby 
causing or aggravating malnutrition which results in retarded growth and physical 
development. Consequently, symptoms like retarded cognitive development, iron-
deficiency anaemia, abdominal pains and related health problems are characteristic 
features of most heavy helminth infections (CROMPTON and NESHEIM, 2002; 
KIRWAN et al., 2009). Many researchers (BROOKER et al., 2004; BORKOW and 
BENTWICH, 2006) have observed a decline in host immune status as a result of 
helminth infection thereby increasing the host susceptibility to other pathogens. 
 
1.7 Aims and objectives 
 
Helminth infections affect the immune system and enhance development of 
secondary infections such as microbial diseases. In South Africa, especially the rural 
areas, the prevalence rate is alarming because factors such as poor sanitation and 
malnutrition that pre-dispose humans to these infections abound. Also, there is 
growing resistance to the available chemotherapeutics with frequent cases of re-
infection occurring. It is desirable to investigate some of the medicinal plants used in 
helminth infection treatment for efficacy and possible identification of new therapeutic 
compound(s). Medicinal plants provide mixtures of many chemical compounds 
possessing multiple biological activities. For this reason, it was deemed important to 
screen the medicinal plants studied for other biological activities especially those 
with symptoms associated with helminth infections. The findings of this work are 
expected to serve as a preliminary phase in validating investigated plants as 
anthelmintics, to provide a homecare herbal remedy against helminth infections and 
to contribute to the expanding ethnopharmacological field in South Africa. 
 
The aims of this research were: 
 to evaluate some of the pharmacological activities including anthelmintic, 
antimicrobial and anti-inflammatory of South African plants used as anthelmintics; 
 to investigate some of the medicinal plants for possible plant part substitution to 
promote conservation; and 
 to determine the phytochemical composition of the investigated plants. 
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Ethnopharmacology is the scientific study encompassing ethnic groups, their health 
in relation to their physical habits as well as the methodology in the creation and use 
of medicines. The main aim of this interdisciplinary field is the biological evaluation of 
the effectiveness of traditional medicine. An ethnopharmacological approach to drug 
discovery has been shown to be an effective and faster means of discovering new 
pharmaceuticals and bioactive compounds from higher plants (FARNSWORTH, 
1994). Traditional medicinal plant usage in various regions of the world has been 
extensively documented by various workers (WATT and BREYER-BRANDWIJK, 
1962; MAGASSOUBA et al., 2007; HUSSAIN et al., 2008a; HEINRICH et al., 
2009). The literature provides information such as the plant part used, preparation 
method and dosage that enhances the investigation process of the medicinal plants. 
 
The collection, preservation, extraction and storage of the plant material are 
important steps in a scientific study. Generally, abiotic and biotic factors such as 
light, temperature, moisture and microbes affect the chemical composition of plant 
material. For instance, the plant chemical composition changes under variable 
conditions when necessary precautions are not taken during collection and 
preparative stages of plant material harvesting for scientific study (MAKKAR, 2000). 
For most pharmacological and phytochemical analyses, extraction of dried plant 
material is preferred to using fresh plant material. The dried plant material is easier 
to handle and more stable because water content in fresh plant material changes 
over time causing a wide variation in plant chemical composition and properties 
(MAKKAR, 2000). 
 
The extraction of plant material using different solvents is based on the biological 
concepts of permeability of the plant cells. Dried plant material extraction can be 
achieved using different solvent systems. These include the use of a single solvent 
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or a series of solvents (such as hexane, ethyl acetate, and methanol) of increasing 
polarity either sequentially or non-sequentially. The dried plant material is extracted 
using different solvents to obtain the bioactive compound(s) present in it for 
pharmacological investigation. It is importance to use a similar extraction method 
employed by the local people for traditional medicinal plant research (GURIB-
FAKIM, 2006). This will enhance the extraction of the same natural bioactive product 
used by the people and probably help in validation of a medicinal plant.  
 
2.2 Materials and methods 
 
The general methods and techniques used for the collection, preservation, 
preparation and storage of the plant materials are detailed below. 
 
2.2.1 Plant collection 
 
A total of 11 plants (Table 2.1) that are used traditionally to treat helminth infections 
were selected from the available literature for investigation (WATT and BREYER-
BRANDWIJK, 1962; HUTCHINGS et al., 1996; VAN WYK et al., 1997; POOLEY, 
1998; OKUJAGU et al., 2006). Plant material of these species was collected from 
the University of KwaZulu-Natal (UKZN) Botanical Garden, Pietermaritzburg and 
Mount Gilboa (29º 15.450' S, 30º 20.289' E) between February and April 2009. 
Voucher specimens of the plants were deposited in the UKZN Herbarium, 
Pietermaritzburg. 
 
2.2.2 Extract preparation 
 
The plant material was oven dried at 50 ºC for 3-5 days depending on the moisture 
content, ground into fine powders through a 1 mm ring sieve using an Ultra 
Centrifugal Mill (ZM 200, Retsch®, Germany) and stored in airtight containers under 
cool dark conditions at room temperature. 
 
Independently, 1 g of ground plant material was extracted with 10 ml of four different 
solvents namely; petroleum ether (PE), dichloromethane (DCM), ethanol (EtOH) and 
water. The ground plant material in the extracting solvent was placed on ice in a 
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sonication bath (Julabo GMBH, Germany) for 1 h. The extract was filtered under 
vacuum through Whatman No. 1 filter paper. Organic solvent extracts were 
concentrated in vacuo with a rotary evaporator (Bϋchi, Germany) at 30 ºC while the 
water extracts were collected into pre-weighed glass jars and freeze-dried using a 
freeze-drying unit. The concentrates obtained were transferred to pre-weighed glass 
pill vials and placed under a stream of cold air for complete dryness. The percentage 
yield of extract was determined in terms of the mass of the starting ground material. 
The prepared crude extracts were stored in clean airtight glass pill vials at 10 ºC in 
the dark until required for analysis. 
 
2.3 Results and discussion 
 
The family, plant part(s), and ethnopharmacological uses for each plant species 
selected for investigation are shown in Table 2.1. A total of nine families were 
selected with at least one species investigated from each family. For Crassulaceae, 
two varieties of Cotyledon orbiculata (var. dactylosis and orbiculata) which were 
readily available were selected for investigation. 
 
The plant material was dried to prevent the fluctuations in chemical composition as a 
result of moisture content. Grinding of dried plant material to powders was to 
increase the surface area for greater extraction with the extracting solvents. The 
plant material was stored under dark conditions to prevent enzymatic degradation 
that could be stimulated by light and to limit microbial growth (GURIB-FAKIM, 2006). 
The different solvents were used due to the difference in polarity to enhance 
extraction of all biologically active compounds in the plant material. Although, the 
solvent mainly used for herbal preparation in traditional medicine is water and a few 
preparations utilize water-alcohol for rapid results (ZSCHOCKE and VAN STADEN, 
2000; SPARG et al., 2002), the solvents (PE, DCM, EtOH) were used for 
consistency and total extraction of potential bioactive compounds (McGAW and 
ELOFF, 2008). Ice was added to the sonication bath to prevent breakdown of 




Table 2.1: South African plants used as anthelmintics based on ethnobotanical 








Plant part screened 
 








Dried leaves or roots and wood are 
used as anthelmintics (HUTCHINGS 
et al., 1996; VAN WYK et al., 1997). 
 
Asteraceae Felicia erigeroides DC. 
A.AREMU 3NU 
Leaves, Stems 
Hot leaf infusions are administered as 
enemas for intestinal parasites and 
abdominal pains and also as 





Senna petersiana (Bolle) Lock. 
A.AREMU 7NU 
Leaves 
Senna species are used 
pharmaceutically in laxative 
preparations. Root and leaf infusion 
are used as a purgative to treat 
constipation, stomach-ache and 
intestinal worms (VAN WYK et al., 
1997; HUTCHINGS et al., 1996). 
 




Leaves are eaten as vermifuge and 
applied as a hot poultice to treat boils, 
earache and inflammation (WATT and 
BREYER-BRANDWIJK, 1962; VAN 
WYK et al., 1997). 
 
Crassulaceae Cotyledon orbiculata var. orbiculata 
A.AREMU 5NU 
Leaves, Stems 
Leaves are eaten as vermifuge and 
applied as a hot poultice to treat boils, 
earache and inflammation (WATT and 
BREYER-BRANDWIJK, 1962; VAN 




Cyathea dregei Kunze 
A.AREMU 2NU 
Leaves, Roots 
Dried roots used as anthelmintic 










Plant part screened 
 









Used as purgatives and ascarifuges in 










Plant decoctions have purging effects 




Ocimum basilicum (L.) 
A.AREMU 6NU 
Leaves 
Juice of leaves are used to expel 
worms; leaves are used for respiratory 
disorders, dysentery, constipation 
(OKUJAGU et al., 2006). 
 
Rosaceae Leucosidea sericea Eckl. & Zeyh. 
A.AREMU 4NU 
Leaves, Stems 
Used as an astringent and an 
ingredient with other plants in a 
vermifuge; ground leaf paste is used 
for ophthalmia (WATT and BREYER-







Clerodendrum myricoides (Hochst.) 
Vatke. 
A.AREMU 8NU 
Leaves, Stems  
 
Root and leaf infusions are taken as 
anthelmintics; they are also used for 
pains in the chest, colds, bleeding of 
the gums and indigestion 










Table 2.1: continued... 
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2.3.1 Ethnopharmacological approach for plant selection 
 
The use of ethnopharmacological information in the selection of plants is based on 
the therapeutic use by an ethnic group (SOUZA BRITO, 1996) and has been 
established to provide a valuable short cut in discovering plants with good biological 
activities (GENTRY, 1993). KHAFAGI and DEWEDAR (2000) highlighted the 
advantages and limitations of the different approaches to drug discovery and 
concluded that an ethnopharmacological approach as opposed to random screening 
yielded the best results. Recently, most pharmaceutical companies use this 
indigenous knowledge for identification of bioactive compound(s) that could be use in 
the synthesis of new drugs. It is believed that valuable medicinal plants are those 
with a long history of usage in different localities and are also presumed to be safer 
compared to plants with no ethnomedical records (FABRICANT and 
FARNSWORTH, 2001). 
 
A different set of metabolites is sometimes produced in different anatomical plant 
parts such as roots, corms, stems, leaves and flowers. Related plants (same genus) 
and different parts of the same plant (such as stems, roots, leaves, and twigs) have 
been reported to occasionally exhibit similar pharmacological properties (JÄGER et 
al., 1996; AMOO et al., 2009a). In addition, ZSCHOCKE et al. (2000) emphasized 
the need to enhance conservation by investigating other plant parts especially leaves 
and twigs for similar pharmacological activity regardless of the part traditionally used. 
In this view and for higher chances of discovering of bioactive compound(s) as well 
as for comparative purpose, different parts and different species within the same 
genus were selected for investigation. 
 
2.3.2 Effect of extracting solvents on percentage yield 
 
The yields of extracts after extraction and the drying are given in Table 2.2. 
Generally; extracting with water resulted in the highest quantity of crude extract, 
while PE gave the least quantity of crude extract except for the leaves of the two 
Cotyledon species where EtOH had the lowest yield.  
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Twigs 5.9 7.0 10.0 20.3 
Clerodendrum myricoides 
 
Leaves 3.2 3.5 4.4 30.3 
Stems 0.4 0.6 3.6 13.8 
Cotyledon orbiculata var. dactylopsis 
 
Leaves 2.6 3.3 1.8 30.8 
Stems 0.6 1.0 0.8 17.5 
Cotyledon orbiculata var. orbiculata 
 
Leaves 1.7 2.1 1.5 33.8 
Stems 0.5 0.7 3.0 15.6 
Cyathea dregei 
 
Leaves 4.0 4.4 6.4 6.8 
Roots 0.2 0.3 1.0 2.3 
Felicia erigeroides 
 
Leaves 1.5 4.5 6.4 20.2 
Stems 0.3 0.6 1.2 10.2 
Hypoxis colchicifolia 
 
Leaves 2.4 3.0 5.6 7.1 
Corms 0.3 0.5 10.6 24.4 
Hypoxis hemerocallidea 
 
Leaves 0.8 1.1 2.0 6.2 
Corms 0.2 0.4 33.4 35.0 
Leucosidea sericea 
 
Leaves 3.4 4.4 9.0 10.0 
Stems 0.4 0.5 1.7 3.0 

















The high polarity of water probably accounted for the high yield because both polar 
and some less polar compounds were extracted. The lowest yield (0.2%) was 
obtained in the PE root extract of C. dregei and corm extract of H. hemerocallidea 
(0.2%). A water extract of S. petersiana leaves gave the highest yield (35.2%). 
Beside PE and DCM extracts of A. oppositifolia twigs, the leaf part generally yielded 
more extracts than the other plant parts. In most plant species, the leaf is known to 
be more complex and probably contains more compounds than other plant organs 




An ethnopharmacological approach was used for the selection of the plant species 
investigated. The plants were selected based on their documented anthelmintic 
property across Africa and availability in South Africa. As expected, the extract yield 
increased when using solvents of increasing polarity. The general trend of the yield 
obtained in ascending order was PE < DCM < EtOH < water. The extraction of active 
principles from the medicinal plants for pharmacological evaluation was to some 

















Helminth diseases may arise as a result of infection of the body by parasitic worms 
(MAIZELS and YAZDANBAKHSH, 2003). These infections have been with mankind 
for centuries and still remain prevalent in most regions of the world (COX, 2002). An 
estimated 50% of the world‟s population is affected at some stage of their life, and 
the prevalence of gastrointestinal nematode infections have remained stable over 
the last 50 years (CHAN, 1997). There is a higher prevalence in Asia, Latin America 
and sub-Saharan Africa as these regions have warmer and more humid climatic 
conditions that favour larval development and survival of most helminth species 
(KAPPUS et al., 1994). Studies in different regions have shown that factors such as 
surface temperature and high rainfall are important in the prevalence of soil-
transmitted helminth (STH) infections (APPLETON and GOUWS, 1996; 
GUNAWARDENA et al., 2005; BROOKER et al., 2006b). 
 
The infecting helminth species, degree of infection and host age, determine the 
clinical symptoms of helminth infection (WANG et al., 2008). A number of factors 
determine the parasite pathogenicity and include: exposure and entry; adherence 
and replication; cell and tissue damage; disruption, evasion and inactivation of host 
defences (MURRAY et al., 1998). These factors distinguish parasite infections from 
other infections that are caused by fungi, bacteria and viruses. This could be linked 
to the chronic nature and long duration of most parasitic diseases in humans. 
Generally, helminth infections are regarded as a global problem of medical, 
educational and economic significance because of the long term chronic 
inflammatory disorders and disabling effects when left untreated (STEPEK et al., 






3.1.1 Human helminth infections 
 
Humans are affected by approximately 342 helminth species (CROMPTON, 1999), 
of which 197 are considered as primary inhabitants of the gastro-intestinal tract 
(HORTON, 2003). Globally, only an estimated 20 species are known to cause 
diseases. Nematodes are regarded as the most important parasitic group as a result 
of their wide spread and global distribution (HOTEZ et al., 2008). Examples of the 
helminth species of greatest medical interest are Ascaris lumbricoides, Necator 
americanus, Schistosoma species, Strongyloides stercoralis and Trichuris trichiura 
(HORTON, 2003; BETHONY et al., 2006). The disease prevalence, infection 
patterns and clinical significance of three common types of helminth infections are 
discussed in the sections below. 
 
3.1.1.1      Ascariasis 
 
Ascariasis is more pronounced in many developing countries in Africa, South 
America as well as Asia. An estimated 1.5 billion people are infected worldwide 
(CROMPTON, 1999). Ascariasis (roundworm infection) is the most common 
helminth infection of humans and is caused by members of the genus Ascaris.  
A. lumbricoides is the largest intestinal roundworm and can grow to an estimated  
20-35 cm in length in the intestine of human (MURRAY et al., 1998). 
 
An individual can be infected through ingestion of food contaminated with faeces 
containing the Ascaris eggs. The eggs hatch in the jejunum, penetrate the mucosa 
and are carried through the hepatic circulation to the heart and lungs after which they 
re-enter the stomach via the tracheae and oesophagus before growing to adulthood 
in the small intestine. Adult worms live in the small intestine where they lay large 
numbers of eggs that are passed out with the faeces into the soil for further re-
infection of new hosts (PETERS and GILLES, 1995). After maturity and fertilization, 
the female can produce about 200 000 eggs per day for as long as a year. Fertilized 





Infections are usually asymptomatic, especially if the number of worms is small. The 
most common symptoms are diarrhoea and upper abdominal discomfort of varying 
degrees (SHEOREY et al., 2007). Infection may, however, be accompanied by 
inflammation and fever (MURRAY et al., 1998). Large numbers of adult worms can 
cause mechanical blockage of the intestinal tract, especially in children, and worms 
penetrating the host‟s intestinal wall can result in peritonitis (SHEOREY et al., 2007). 
During movement through the lungs, the larvae may provoke an immune-mediated 
hypersensitivity response due to metabolic excretions and secretions of adult worms 
(CROMPTON, 2001). In addition, the worm‟s migration to other parts of the body can 
cause morbidity and sometimes death, by compromising nutritional status, affecting 
cognitive processes, inducing tissue reactions such as granuloma, and provoking 
intestinal obstruction or rectal prolapse (MAGUIRE, 2005; SHEOREY et al., 2007). 
 
3.1.1.2     Hookworm infection 
 
Hookworm infection remains one of the most common chronic infections of humans 
with an estimate of 576-740 million individuals affected worldwide (BETHONY et al., 
2006). It is predominantly found in areas of rural poverty in China and sub-Saharan 
Africa (De SILVA et al., 2003). Necator americanus and Ancylostoma duodenale are 
the two most common hookworm species known to affect humans (BROOKER et 
al., 2004). 
 
In the human host, the third larval stage (L3) is the infective stage and it passes 
through the skin as a result of walking bare-footed in areas contaminated with faecal 
matter. N. americanus L3 larvae may invade the buccal epithelium when they enter 
through the mouth (BROOKER et al., 2004). The larvae are able to penetrate the 
skin of the foot and once inside the body, they migrate through the vascular system 
to the lungs and trachea. They pass down the oesophagus into the digestive system 
and eventually to the intestine where the larvae mature into adult worms. These 
worms feed by sucking blood from injured intestinal tissues. Egg laying starts 4-6 
weeks after infection and may remain viable for as long as 5 years. Adult worms lay 
as many as 10 000-20 000 eggs per day which are released into the soil with faeces. 
As a result, the non-infective larvae hatch and within 2 weeks develop into L3 larvae 
(MURRAY et al., 1998; HOTEZ et al., 2009). 
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A mild hookworm infection is asymptomatic and a common mild symptom that 
occurs soon after infection is the “ground-itch”. This is an allergic reaction at the site 
of parasite penetration and entry, common in patients infected with N. americanus 
(BETHONY et al., 2006). However, signs of advanced severe infection include 
anaemia and protein deficiency that lead to high morbidity associated with hookworm 
infection (GILGEN et al., 2001). In addition, scientific evidence has established a 
direct relationship between the number of adult hookworms in the human gut and the 
amount of intestinal blood loss (STOLTZFUS et al., 1997). Intestinal blood loss 
leads to severe iron-deficiency anaemia (IDA) reported to account for 20% of 
maternal deaths during pregnancy globally (CROMPTON, 2000). Furthermore, 
intestinal sites may become susceptible to bacterial infection when the worms 
migrate along the intestinal mucosa (MURRAY et al., 1998). 
 
3.1.1.3     Schistosomiasis 
 
Schistosomiasis, otherwise known as bilharziasis, or snail fever is a tropical parasitic 
disease caused by several types of fluke of the genus Schistosoma. The three main 
species associated with several human diseases are S. mansoni, S. japonicum and  
S. haematobium (GRYSEELS et al., 2006). In Africa, the two most common species 
are S. haematobium transmitted by Bulinus snails causing urinary schistosomiasis 
and S. mansoni transmitted by Biomphalaria snails causing hepatic schistosomiasis 
(MURRAY et al., 1998). The disease is endemic in 74 countries with an estimated 
800 million individuals at risk and 200 million people infected (MØLGAARD et al., 
2001). African countries account for 90% of the infections and in terms of the number 
of people at risk and infected, schistosomiasis ranks second (behind malaria) among 
the parasitic diseases (STEINMANN et al., 2006). 
 
The parasite infective forms, known as cercariae, are released from the intermediate 
host (snail) and penetrate a suitable human host‟s skin. The cercariae secrete 
enzymes that break down the skin‟s protein to allow penetration of the cercarial head 
through the skin, leading to the formation of a migratory schistosomula stage. These 
immature forms of the parasitic schistosome may remain in the skin for 48 h before 
locating a suitable blood capillary. The schistosomula travel through the lungs, heart, 
and eventually to the liver, where they mature into male or female adult worm pairs 
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in about 45 days. S. japonicum migrates faster than S. mansoni and usually reaches 
the liver within 8 days of penetration. Juvenile worms of both species develop an oral 
sucker after arriving in the liver which the parasites use to feed on the red blood 
cells. Parasites reach maturity in 6-8 weeks and begin the production of eggs.  
S. mansoni produces up to 300 eggs while S. japonicum may produce up to 3000 
eggs per day. Some of the produced eggs are passed out through urine and faeces 
which later hatch to release miracidia (an intermediate life cycle stage) that 
undergoes development and multiplication in the snail‟s digestive gland in  
4-6 weeks. Worm pairs can live in the body for an average of four and half years, but 
may persist up to 20 years. About 50% of the worms become trapped in the 
mesenteric veins or are washed back and lodged in the liver. The trapped eggs 
mature normally and secrete antigens that elicit a vigorous immune response 
resulting in pathology classically associated with schistosomiasis (MURRAY et al., 
1998). 
 
Schistosomiasis is a chronic disease and acute pathology may occur a few weeks 
after initial infection by the parasite (GRYSEELS et al., 2006). Common symptoms 
associated with the acute state include abdominal pains, genital sores, fever and 
fatigue (HOTEZ et al., 2009). Sub-clinical symptoms such as mild anaemia and 
malnutrition are frequently observed among infected youth (KING et al., 2005).  
A study in northwest Tanzania carried out among pregnant woman revealed an 
increased risk of anaemia as a result of heavy infection with S. mansoni (AJANGA 
et al., 2006). 
 
3.1.2 Treatment of helminth infections 
 
The control of helminth infections requires a multi-faceted approach due to the 
complex life cycle of most causative organisms and environmental influences 
(WHITFIELD, 1996). Proper health education, good hygiene and improved 
sanitation, as well as use of anthelmintic chemotherapy such as levamisole, 
albendazole and pyrantel, are the major control measures against helminth 
infections (SAVIOLI et al., 1992; STEPEK et al., 2006). The use of broad spectrum 
chemotherapy is useful for cases of multiple worm infection in humans (BOOTH et 
al., 1998). However, only three classes of broad spectrum anthelmintics are 
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available and the chances of discovering novel anthelmintics are very low due to the 
limited number of anthelmintic drug research projects in academic laboratories and 
pharmaceutical industries globally (GEARY et al., 1999a). 
 
The latest drug class development dates back to the early 1980s when ivermectin, a 
member of class 3 anthelmintic drugs, called macrocyclic lactones, was discovered. 
These drugs act by paralysis of body-wall muscles in nematodes (BEHNKE et al., 
2008). Subsequently, other ivermectin analogues such as moxidectin, doramectin 
and abamectin, which have distinct properties for specific helminth infections were 
developed (GEARY, 2005). Prior to the discovery of invermectin, two other classes 
of drugs were used. Levamisole, an example of the class 2 imidazothiazoles, acts by 
stimulating the nicotinic acetylcholine receptors and result in paralysis of the worms 
which can then be washed out the intestine by peristalsis (STEPEK et al., 2006). 
The class 1 drugs, known as the benzimidazoles (albendazole and mebendazole), 
bind to free β-tubulin, inhibiting its polymerization and thereby interfering with the 
microtubule-dependent glucose uptake by the parasite (RANG et al., 2003). 
 
Despite the efficacy and relatively good safety margins of most available 
chemotherapies, there is still a growing concern about potential problems of acquired 
resistance as varying degrees of resistance in nematode populations in human and 
livestock have been reported globally (ALBONICO et al., 2003; JABBAR et al., 
2006). The problem of re-infection after chemotherapy (KIRWAN et al., 2009), 
adverse drug complications in certain groups of people such as hepatitis patients, 
pregnant and lactating woman (SAVIOLI et al., 2003) as well as the lack of a potent 
and safe macrofilaricide (WHITFIELD, 1996) have necessitated the search for new 
anthelmintic substances. As the plant kingdom remains poorly explored (RATES, 
2001), more effort is now being directed to the discovery of new anthelmintics of 
plant origin (ATHANASIADOU et al., 2007). 
 
For centuries, indigenous people have utilized plants and their extracts for the 
treatment of a variety of human and livestock gastro-intestinal parasites (WALLER 
et al., 2001). Some of the earliest known medicinal anthelmintic plants include 
Carica papaya, Ficus species and Ananas comosus. Until recently, most medicinal 
plant anti-parasitic activity was based on anecdotal evidence and there is currently 
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an increase in the number of scientific studies aiming to verify, validate and quantify, 
as well as determine the safety of such plant activity (ATHANASIADOU et al., 
2007). Consequently, anthelmintic compounds such as santonin and filicic acids 
have been isolated from Artemisia maritime L. and Dryopterix filix-mas (Maxim.), 
respectively (SETZER and VOGLER, 2006). 
 
3.1.3 Anthelmintic bioassays 
 
Most helminths belong to a very large group of organisms that are widely diverse in 
body structure and in parasitic mechanisms (FENNELL et al., 2004). In view of this, 
important factors such as the type of test organisms, plant extracting methods and 
seasonal variation in plant chemical composition, must be considered when 
evaluating the potential of medicinal plant use in parasite control (ATHANASIADOU 
et al., 2007). 
 
In vivo and in vitro bioassays, as well as a number of test organisms, have been 
employed to screen plants for anthelmintic activity. Both test systems and the 
varieties of organisms employed, have various limitations (JABBAR et al., 2006). 
Most preliminary screening investigation of plants for anthelmintic activity use in vitro 
bioassays (SIMPKIN and COLES, 1981). Generally, the main advantages of using 
in vitro bioassays over in vivo bioassays include the low cost involved and rapid 
turnover that allows for large-scale screening of plants, as well as the low quantity of 
extracts, required for most in vitro investigations (WHITFIELD, 1996; GITHIORI et 
al., 2006). However, in vitro bioassays should be followed by in vivo tests when 
validating the anthelmintic activity of medicinal plants (ATHANASIADOU et al., 
2007). Examples of in vitro test systems include the larval arrested morphology 
assay (LAMA), larval motility assay (LMA), egg hatch test (EHT), colorimetric assays 
and adult development test (ADT) (JABBAR et al., 2006; KOPP et al., 2008). 
 
Although the in vitro Caenorhabditis elegans bioassay has long been employed for 
anthelmintic screening with limited success in discovery of valuable new leads 
(GEARY et al., 1999b), it remains the most suitable test organism for preliminary 
high-through put in vitro screening for broad spectrum anthelmintic activity (GEARY 
and THOMPSON, 2001). In addition, C. elegans is a representative of a large 
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phylum with many parasites (BÜRGLIN et al., 1998), its sensitivity to most 
commercial anthelmintic drugs as well as the ease of culture growth and 
maintenance contribute to its widespread use for anthelmintic screenings (SIMPKIN 
and COLES, 1981). 
 
Many studies using C. elegans require measuring the survival and/or reproductive 
potential of the worms after incubating with the test extracts for a specific time. The 
effectiveness of the tested extracts is often measured based on the worms‟ viability 
(reproduction responses) or mobility (behaviour responses) after the incubation 
period (McGAW et al., 2000). These methods are subjective, often unreliable and 
time consuming. As a result, a visual, qualitative and quantitative worm viability 
assessment has been developed (JAMES and DAVEY, 2007). This technique is a 
colorimetric assay that utilizes metabolic activity as a measure of the viability in the 
investigated organisms and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide-formazan (MTT-formazan) is used as the indicator compound (JAMES and 
DAVEY, 2007). The assay provides a simple method for viability testing in potential 
anthelmintic plant extracts against C. elegans and has the advantage of rapid 
evaluation. 
 
3.2 Materials and methods 
 
For evaluation of the plant material for anthelmintic activity, the techniques employed 
are detailed below. 
 
3.2.1 Extract preparation  
 
Extract preparation was carried out as described in Section 2.2.2. The stored dried 
plant extracts were redissolved at a concentration of 25 mg/ml for use in DMSO for 
organic solvent extracts (PE, DCM and EtOH) and 50 mg/ml for use in distilled water 






3.2.2 Maintenance and storage of Caenorhabditis elegans cultures 
 
Caenorhabditis elegans var. Bristol (N2) was used as the test organism and was 
obtained from our laboratory stock culture. The nematodes were cultured on 
nematode growth (NG) agar (Appendix 1) seeded with Escherichia coli (ATCC 
11775) serving as a food source at 20 ºC under dark conditions (BRENNER, 1974). 
An overnight (18 h) culture of E. coli was made by inoculating a single colony in 5 ml 
of sterilized Mueller-Hinton (MH) broth (Oxoid Limited, England) in a sterile 
McCartney bottle and incubated at 37 ºC in a water bath with an orbital shaker for  
18 h. For the sub-culturing, 5 ml of sterile M9 buffer (Appendix 1) were added to an 
old C. elegans culture plate to wash the nematodes off the plate. Fifty microlitres 
aliquot of the overnight E. coli were transferred to the new NG agar plates and 
spread across the plate using a glass rod. Thereafter, 500 µl of the old C. elegans 
culture in M9 buffer were transferred to the new NG agar plate already seeded with  
E. coli. The newly cultured NG agar plates were incubated at 20 ºC under dark 
conditions until required. The sub-culturing was repeated every 6 weeks to maintain 
the strength and viability of the nematodes. 
 
3.2.3 In vitro anthelmintic bioassay 
 
A rapid in vitro colourimetric assay used in the determination of nematode free-living 
larvae viability, as described by JAMES and DAVEY (2007), with slight 
modifications, was employed in evaluating the minimum lethal concentration (MLC) 
values of plant extracts against C. elegans. A 3-day-old C. elegans culture was 
prepared by sub-culturing a stock nematode plate as described above (Section 
3.2.2). The NG agar plate was seeded with an autoclaved E. coli culture to serve as 
a food source for the nematodes, without resulting in a colour change to the indicator 
compound. The 3-day-old C. elegans culture was washed with 5 ml of M9 buffer into 
a sterile McCartney bottle and the optical density (OD) at 530 nm was measured 
using a UV-visible spectrophotometer (Varian Cary 50, Australia). Thereafter, 5 ml of 
M9 buffer were adjusted with the appropriate volume of the prepared stock C. 
elegans culture to obtain a mixture in the OD530 range of 0.04-0.06, which was 
sufficient for a microtitre plate. Similar dilutions were made to obtain enough  
C. elegans culture required for the bioassay. 
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Sterile distilled water (100 µl) was added to each well in a 96-well microtitre plate 
(Greiner Bio-one GmbH, Germany). From the redissolved plant extracts, aliquots of 
100 µl were added to the first well of the microtitre plate (row A) and diluted two-fold 
serially (column 1-12 downward: A to H). Levamisole (100 µl of 1 mg/ml) was also 
two-fold serially diluted with water and this served as the reference anthelmintic 
drug. From the prepared C. elegans mixture, aliquots of 50 µl (containing 
approximately 100 individuals of C. elegans) were added to the wells of the microtitre 
plate. DMSO, sterile water and C. elegans cultures were included in the test as 
controls. The final concentration of the extracts in the microtitre plate ranged from 
0.065 to 8.33 mg/ml and 0.13 to 16.67 mg/ml for organic solvent and water extracts, 
respectively. To reduce evaporation and prevent contamination, the microtitre plates 
were covered with parafilm and incubated at 20 ºC for 48 h. 
 
After incubation, 50 µl of 1.25 mg/ml p-iodonitrotetrazolium chloride (INT) (Sigma-
Aldrich, Germany) were added to all the microtitre plate wells and incubated further 
at 20 ºC for 24 h. Active organisms biologically reduce the colourless INT to a pink-
red colour (McGAW et al., 2007). No colour change indicated inhibition of the 
nematodes and the concentration of the lowest clear well was recorded as the MLC 
value of the extract. Extracts were screened in duplicate and the experiment was 
performed twice. 
 
3.3 Results and discussion 
 
A total of 80 extracts were screened for anthelmintic activity and the MLC values of 
all the extracts are presented in Table 3.1. The MLC is defined as the lowest 
concentration that causes mortality in a liquid culture. The possible mechanism of 
action of the extract against the C. elegans can be considered to be a direct toxic 
effect as a result of the assay method employed for this study. INT was used as an 
indicator in place of MTT-formazan because it has been shown that INT is more 
stable over time (ELOFF, 1998a). 
 
In comparison to studies on antimicrobial activity, scientific evaluation or standards 
comparing the efficacy of plant extracts to commercial anthelmintics, as well as 
determining the level of anthelmintic activity, are limited. As a result, there is much 
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experimental variability that has led to an increased apparent conflict of results on 
anthelmintic activity by plant extracts (ATHANASIADOU et al., 2007). Most 
anthelmintic screening is reported as an estimate of the percentage of nematode 
survival, or the use of a scoring system, after incubation of the extracts and 
nematode culture for a certain period. In this study, three levels of anthelmintic 
activity were defined, MLC values less than 1 mg/ml were considered as high 
anthelmintic activity, from 1 mg/ml to less than 4 mg/ml as moderate activity while 
values greater than 4 mg/ml to 16.67 mg/ml were regarded as low anthelmintic 
activity. These definitions were based on factors such as the acceptable noteworthy 
level of crude extract concentration as used in other screening bioassay as well as 
the anthelmintic activity exhibited by various extract concentrations as reported in 
other preliminary anthelmintic screening assays (McGAW et al., 2007; VAN 
VUUREN, 2008). 
 
3.3.1 Anthelmintic activity of investigated plant extracts  
 
The MLC values ranged from 0.13 to 16.67 mg/ml, with MLC values greater than 
16.67 mg/ml being regarded as having no activity at the screening concentration. 
The lowest MLC value of 0.13 mg/ml, corresponding to the best anthelmintic activity, 
was displayed by the DCM extract of H. colchicifolia leaves. Water extracts of    
C. orbiculata var. dactylopsis (leaves and stems), C. orbiculata var. orbiculata 
(leaves) and F. erigeroides (stems) showed no anthelmintic activity at the maximum 
screening concentration. In summary, 19 extracts had high anthelmintic activity, 34 
extracts displayed moderate activity and 27 extracts had low or no anthelmintic 
activity. 
 
Apart from H. hemerocallidea, all the plant species had at least one of its extract 
showing a high anthelmintic activity. The potential anthelmintic activity shown by 
these plants further confirms the importance of using an ethnopharmacological 
approach in screening plants as a source of novel pharmaceuticals. This approach 
provides a valuable short-cut by taking advantage of information available from 
traditional healers and ethnopharmacological records (ELGORASHI and VAN 
STADEN, 2004). 
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Table 3.1: Minimum lethal concentration (MLC) values (mg/ml) of plant extracts 
against C. elegans in the in vitro anthelmintic bioassay. Values in bold  








































Stems 2.08 2.08 2.08 2.08 
 












Stems 4.17 4.17 4.17 >16.67 
 







































































































Extracting solvent: PE = Petroleum ether, DCM = Dichloromethane, EtOH = Ethanol. 
The MLC of the reference levamisole was 40 µg/ml. 
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The extracts of C. dregei leaves exhibited better anthelmintic activity than the root 
extracts. Interestingly, traditional healers use the dried roots of this fern as an 
anthelmintic (HUTCHINGS et al., 1996). The destructive harvesting of the roots for 
medicinal uses is probably responsible for the plant being listed as one of the 
threatened plants of southern Africa as in Lesotho and South Africa (TALUKDAR, 
2002). Similarly, the Hypoxis species leaf extracts had better anthelmintic activity 
than the underground corms. Indiscriminate and over-harvesting of underground 
parts such as roots and corms endangers plant survival (JÄGER and VAN 
STADEN, 2000). Different compounds could be responsible for the difference in 
activity levels (STEENKAMP et al., 2006) or a variation in the quantities of bioactive 
compounds in the two plant parts providing a possible explanation for the higher 
anthelmintic activity in the leaf extracts. Most importantly, these results support the 
ideal of investigating alternative plant parts as a substitute to ensure sustainable 
non-destructive plant harvesting (ZSCHOCKE et al., 2000). 
 
Members of the genus Acokanthera are well known to be poisonous due to the 
presence of several toxic cardiac glycosides (VAN WYK et al., 2002). In a previous 
study, A. oblongifolia did not exhibit any anthelmintic activity against C. elegans in 
respect of both nematode mortality and reproductive ability in in vitro assays 
(McGAW et al., 2000). A. oppositifolia have been reported to have a considerable 
amount of phenolic compounds (ADEDAPO et al., 2008). In view of different reports, 
the high anthelmintic activity displayed by PE and EtOH extracts of A. oppositifolia 
leaves deserves further investigation for its safety as the extracts may well be toxic 
to humans over and above to their therapeutic value. Toxic principles such as 
tyledoside and three bufadienolide glycosides (orbicuside A, B and C) are present in 
Cotyledon species (HUTCHINGS et al., 1996) and the noteworthy activity of this 
species might be as a result of the lethal effect of these principles on C. elegans. 
 
The organic solvent extracts of S. petersianna displayed moderate to high 
anthelmintic activity while the water extract had low activity. SPARG et al. (2000) 
also reported a significant lethal activity of the water extract against the 
schistosomula at 6.25 mg/ml in an in vitro assay. The active constituents of the 
different parts of the plant have been identified as anthraquinone glycosides (WATT 
and BREYER-BRANDWIJK, 1962) and probably accounted for the anthelmintic 
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activity. The leaf extracts of O. basilicum contain many essential oils such as 
limonene and α-terpineol (RUNYORO et al., 2010) which are known to possess 
pharmacological activities and may well be responsible for the high anthelmintic 
activity against C. elegans observed in this study. 
 
As shown in Figure 3.1, the organic solvent extracts (PE, DCM and EtOH) had 
better anthelmintic activity than the water extracts. A total of 12 water extracts 
showed low or no anthelmintic activity. Although some herbal preparations employ 
alcohol for rapid action, water is the most common solvent used in traditional 
medicine, (SPARG et al., 2002). The use of water for extraction naturally limits the 
type and amount of compounds extracted from a plant (ELOFF, 1998b). Non-polar 
principles are better extracted with organic solvents such as PE, DCM and EtOH, as 
used in this investigation. EtOH had the highest number (8) of extracts that exhibited 

























MLC < 1 mg/ml 
MLC from 1 to 4 mg/ml 
MLC > 4 mg/ml 
PE DCM EtOH Water
 
Figure 3.1: Number of extracts exhibiting different levels of anthelmintic activity as a 
result of the solvent types used for the plant extraction. PE = Petroleum ether,  
DCM = Dichloromethane, EtOH = Ethanol, MLC = Minimum lethal concentration. 
 MLC < 1 mg/ml, MLC ≥ 1 to ≤ 4 and MLC > 4 mg/ml indicate high, moderate and low 





In this investigation, 19 plant extracts exhibited high anthelmintic activity against  
C. elegans, thereby supporting their use as anthelmintic plants in traditional 
medicine. Conversely, the absence of significant (low or no) anthelmintic activity in 
other extracts could be due to factors such as insufficient active principle(s) and 
antagonistic effects by other compounds against the plant extracts active principle(s) 
and not necessarily the inactivity of the plant extracts (TAYLOR et al., 2001). 
 
The in vitro bioassay served as a means of rapidly screening for potential 
anthelmintic activity in the plant extracts as well as providing evidence for the 
possible mechanism of the active compound(s) on the test organism (C. elegans). 
However, in view of the differences between in vitro and in vivo environments, these 
results remain indicative of the anthelmintic potential of the plant extracts and further 
investigations involving in vivo studies and parasitic helminth organisms would be 
necessary for valid conclusions. In addition, bioactivity-guided isolation and safety of 
the active compound(s) would be necessary, and non-toxic and very potent active 
compound(s) could serve as leads for the development of new anthelmintic drugs for 












Infectious diseases represent a serious health problem and are part of the leading 
causes of death globally. The increasing microbial resistance to antibiotics is 
gradually aggravating this situation over time (BANDOW et al., 2003; KUETE et al., 
2009). Recently, developing countries have witnessed an increased mortality rate 
due to infectious diseases such as diarrhoea and dysentery, mainly caused by 
intestinal infection (LONGANGA OTSHUDI et al., 2000). Common organisms 
associated with intestinal infection include viruses, bacteria, protozoa and helminths. 
Scientific evidence also suggests that both synergism and antagonism between 
helminth infections and other pathogenic infections are increasing (COX, 2001). 
Parasites can either reduce host immunity or boost the immune system against 
certain other diseases such as autoimmune disorders (for example: Crohn's disease) 
(HUNTER and McKAY, 2004). Parasites such as helminths do not always cause 
obvious diseases but the host‟s health integrity could be compromised due to the 
metabolic activities of the parasites such as nutrition, excretion and reproduction 
(DEACON, 2006). This probably accounts for the increased susceptibility and 
enhances the progression of bacterial diseases such as tuberculosis and other 
opportunistic infections among helminth hosts (BENTWICH et al., 1995; BROOKER 
et al., 2004). In addition, microorganisms such as bacteria (Escherichia coli, 
Klebsiella pneumoniae and Staphylococcus aureus) and fungi (Candida albicans) 
have been implicated in the increased infection rate in immune-compromised 
patients globally (SLEIGH and TIMBURG, 1998). 
 
The importance of pharmacological screening of plant extracts for multiple biological 
activities has been extensively documented (HOUGHTON et al., 2005). This 
importance has been demonstrated using diseases such as Alzheimer‟s, diabetes 
and wound healing. The use of multiple bioassays gives a clearer indication of the 
effect of the extracts in relation to the disease state (HOUGHTON et al., 2007). 
According to GURIB-FAKIM (2006), medicinal plants contain complex mixtures of 
compounds that may act individually, additively or in synergy for health improvement. 
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For instance, a medicinal plant containing phenolic compounds may act as 
antioxidant and as an anti-inflammatory agent. Similarly, McGAW et al. (2001) 
studied the pharmacological activity of different Combretum species and four species 
demonstrated a significant bioactivity in more than one bioassay. In another study, 
antibacterial and anti-inflammatory activity of five species in the family Sterculiaceae 
was reported, as a result a variety of compounds were isolated from the plant 
species (REID et al., 2005). Moreover, there is a risk of non-discovery of other 
potentially useful bioactivity of medicinal plants when only a single biological activity 
is investigated (RATES, 2001). 
 
Consequently, antimicrobial activity of the selected South African plants used as 
anthelmintics was investigated. Furthermore, as helminth and microbial infections 
have some common symptoms such as diarrhoea, abdominal pains and 
inflammation, there is a possibility of discovering antimicrobial activity in the 
investigated plants species. 
 
4.1.1 Effect of microbial infections on human health 
 
Although only a small fraction of the thousands of microorganism species are 
harmful, the impact of these pathogenic microorganisms is of great concern in 
human medicine. Most microbes are beneficial, playing a crucial role in the 
ecosystem as decomposers and in the production of antibiotics against human 
diseases (BLACK, 2002). Unfortunately, the living conditions of the majority of 
people in the third-world and most developing countries are characterized by poor 
sanitation, low-levels of hygiene and overcrowded environments (LONGANGA 
OTSHUDI et al., 2000; HOTEZ et al., 2007a). These factors enhance the growth of 
a wide range of microorganisms, especially the virulent pathogens present within the 
community (SLEIGH and TIMBURG, 1998). Due to lower immunity caused by these 
factors, the human skin, mouth, urinary tract, respiratory organs and gastro-intestinal 
tract becomes more susceptible to infection by these microorganisms (EISENSTEIN 
and SCHAECHTER, 1998). Most helminth infections have been attributed to the 
shift in the host-parasite relationship in favour of the parasite, thereby causing 
serious health problems (SLEIGH and TIMBURG, 1998). 
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4.1.1.1     Bacterial infections 
 
Bacterial infections are caused by a wide range of organisms resulting in mild 
infections to life threatening diseases. For instance, Bacillus subtilis is an aerobic, 
rod-shaped, motile, and endospore-forming Gram-positive bacterium. It is a soil 
inhabiting saprophytic organism (SLEIGH and TIMBURG, 1998). Although 
harmless, it occasionally causes some opportunistic infections such as conjunctivitis 
(MURRAY et al., 1998; BUWA and VAN STADEN, 2006). Staphylococcus aureus, 
a Gram-positive coccus bacterium, is part of the normal flora of human skin and 
mucous membranes (MURRAY et al., 1998). This organism is responsible for 
human staphylococcal skin infections (wounds and impetigo), soft tissues (septic 
arthritis) and pneumonia (SLEIGH and TIMBURG, 1998). Escherichia coli, a Gram-
negative rod-shaped bacterium is mostly found inhabiting the human gastrointestinal 
tract (ROSS and PEUTHERER, 1987). The organism has been implicated in most 
bacterial infections including urinary tract infection, travellers‟ diarrhoea, bacteraemia 
and pneumonia (DuPONT, 2006). Klebsiella pneumoniae is a non-motile, rod-
shaped Gram-negative bacterium. The organism is easily observed in culture as it 
forms large colonies. It is also part of the human intestinal and colon flora, having a 
prominent polysaccharide capsule that provides resistance against host defence 
mechanisms (HUGO, 1992). Common human Klebsiella infections include 
community acquired pneumonia, urinary tract infection, lower and upper respiratory 
tract infections (EINSTEIN, 2000). 
 
Other examples of medically important bacterial groups, known to cause various 
infectious diseases in humans, include mycobacterium (tuberculosis), vibrio 
(cholera), neisseria (gonorrhoea) and spirochaetes (syphilis) (SLEIGH and 
TIMBURG, 1998). In South Africa, these infectious bacterial diseases, especially 
tuberculosis are increasing due to the increasing drug resistance and high incidence 






4.1.1.2     Fungal infections 
 
Fungal and yeast infections have a major influence on human health causing 
diseases ranging from mild superficial problems to potentially lethal systemic 
disorders (infections invading internal organs) (KOBAYASHI and MEDOFF, 1998). 
The number of diseases due to fungal infections is however, lower than bacterial 
infections. Approximately 200 of the thousands of fungal species are implicated in 
human diseases (DEACON, 2006). Recently, pathogenic fungal infections have 
been increasing, mostly due to a compromised immune system as humans have a 
high degree of innate immunity to most fungi with exception of the dermatophytic 
type (MURRAY et al., 1998; DEACON, 2006). Most alterations in human immune 
system status are associated with the acquired immune-deficiency syndrome (AIDS), 
increased use of immune-suppressive therapy (cancer chemotherapy, organ or bone 
marrow transplant, X-ray irradiation) and a compromised immune system due to 
parasitic infections such as helminths and protozoans (WALSH and GROLL, 1999; 
FLEMING et al., 2002). 
 
Opportunistic fungal pathogens such as Candida, Mucor and Aspergillus are the 
major causes of morbidity and mortality in humans (GARBINO et al., 2001). For 
instance, C. albicans which is part of the normal flora of the upper respiratory, 
gastrointestinal and female genital tracts is responsible for 90% of fungal infections 
in immuno-compromised patients globally (SLEIGH and TIMBURG, 1998). Likewise, 
SHAI et al. (2008) reported a high occurrence of candidiasis among South African 
HIV/AIDS immune compromised patients. In KwaZulu-Natal, a similar trend with 
associated symptoms such as severe inflammatory diarrhoea and resistance to 
antifungal chemotherapy was observed (MOTSEI et al., 2003). 
 
4.1.2 Treatment of microbial infections 
 
The development of natural products such as antibiotics created a major 
breakthrough in the fight against pathogenic microorganisms. The discovery by 
Alexander Fleming in 1929 of Penicillium nonatum (penicillin) inhibition of 
Staphylococci cultures ushered in the antibiotic era and subsequently led to the 
development of other antibiotics such as streptomycin and tetracycline (SLEIGH and 
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TIMBURG, 1998; MURRAY et al., 1998). Unfortunately, the emergence of drug 
resistant bacteria and the elimination of useful bacterial flora leading to host 
susceptibility to other pathogenic infections, are today major problems associated 
with most antibacterial chemotherapy (GUARNER and MALAGELADA, 2003). 
 
The number of effective chemotherapies against fungal infections is relatively small 
when compared to antibacterial drugs. Common antifungal drugs include 
Amphotericin B, fluconazole and griseofulvin. Amphotericin B is mostly used against 
fungi causing systemic diseases. It binds to the sterols causing disruption in fungus 
cell membrane and finally leads to death of the organism (DEACON, 2006). Most 
antifungal chemotherapeutic agents are toxic in high dosage and have limited 
therapeutic values because of problems with solubility, stability, and absorption by 
the human body (RAPP, 2004). Furthermore, Candida species are resistant to all 
antibacterial antibiotics because fungi are eukaryotic microorganisms (SLEIGH and 
TIMBURG, 1998). 
 
Globally, there is a need for new strategies against the increasing microbial 
infections due to development of resistance to conventional drugs and the adverse 
effects of most available chemotherapy. Fortunately, plants are described as the 
best “combinatorial chemists”, and have the potential to provide novel compounds 
which may turn out to be useful drugs (SAKLANI and KUTTY, 2008). 
 
4.2 Materials and methods 
 
In the quest to evaluate antimicrobial activity, factors such as plant collection, 
bioassay methodology and standardization, as well as various intricacies of 
antimicrobial investigation need to be defined (VAN VUUREN, 2008). These 
parameters as applied in this study are detailed below. 
 
4.2.1 Extract preparation  
 
Extract preparation was carried out as described in Section 2.2.2. The stored dried 
extracts were redissolved at a concentration of 50 mg/ml for use in water for aqueous 
extracts and DMSO for use with organic solvent extracts (PE, DCM and EtOH). 
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4.2.2 Microbial culture storage and maintenance 
 
Although it is ideal to test against specific target microorganisms, taxonomical 
representative species were used in this preliminary antimicrobial screening to avoid 
handling numerous pathogenic microorganisms (TAYLOR et al., 2001). The test 
organisms used for the in vitro antibacterial investigation were; Gram-positive 
bacteria (Bacillus subtilis ATCC 6051 and Staphylococcus aureus, ATCC 12600) 
and Gram-negative bacteria (Escherichia coli ATCC 11775 and Klebsiella 
pneumoniae ATCC 13883). Candida albicans (ATCC 10231) was used for in vitro 
antifungal investigation of the plant extracts. 
 
The microorganism stocks were preserved in sterile cryovials (Greiner, Germany) 
containing glycerol solution (Appendix 2) and stored in an ultra-freezer at -70 ºC 
until required. Mueller-Hilton (MH) agar (Merck, South Africa) was prepared, 
sterilized and poured into sterile plastic Petri dishes and allowed to gel. These MH 
agar plates were stored at 4 ºC for 24 h before the stock bacteria were sub-cultured 
on the MH agar plates. The inoculated plates were incubated at 37 ºC overnight. 
After incubation, the cultured bacterial growth was controlled by storing at 4 ºC until 
required for bioassays. For maintenance of the bacterial strength and viability, 
bacteria were sub-cultured every 42 days (WISTREICH, 1997). C. albicans culture 
was prepared and maintained in a similar manner as the bacteria with the only 
difference being the use of Yeast Malt (YM) agar (Becton Dickinson, USA) in place 
of MH agar (WISTREICH, 1997). 
 
4.2.3 In vitro antibacterial bioassay 
 
The antibacterial activity of the plant extracts was evaluated by determining the 
minimum inhibitory concentration (MIC) using the microplate dilution technique 
(ELOFF, 1998a). An overnight (18 h) culture of the four bacteria (B. subtilis,      
S. aureus, E. coli and K. pneumonia) were prepared by inoculating a single colony of 
each bacterium in 5 ml of sterilized Mueller-Hinton (MH) broth (Oxoid, England) in a 
sterile McCartney bottle and incubated at 37 ºC in a water bath with an orbital 
shaker. The absorbance of each bacterial overnight culture was measured using a 
UV-visible spectrophotometer (Varian Cary 50, Australia) at 600 nm. The overnight 
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bacterial suspension cultures at the following concentrations; 4.8 x 109 CFU/ml  
(B. subtilis), 2.7 x 109 CFU/ml (S. aureus), 7.0 x 1010 CFU/ml (E. coli) and 2.5 x 109 
CFU/ml (K. pneumoniae) were diluted with sterile broth (1:100) and used in the 
screening. 
 
Sterile water (100 µl) was added to each well in a 96-well microtitre plate (Greiner 
Bio-one GmbH, Germany). From the redissolved plant extracts (50 mg/ml), aliquots 
of 100 µl were added to the first well of the microtitre plate (row A) and diluted two-
fold serially (column 1-12 downward: A to H). Neomycin (Sigma-Aldrich, Germany) 
was prepared by diluting 20 µl (10 mg/ml) into 480 µl sterile water in an Eppendorf 
tube. A similar two-fold serial dilution of this prepared neomycin (100 µl) was used as 
the reference drug. From the prepared bacteria cultures, aliquots of 100 µl were 
added to the wells of the microtitre plate. DMSO, sterile water, bacteria-free MH 
broth and bacterial culture were included as the controls. The final concentration of 
the extracts and neomycin in the wells of the microtitre plate ranged from 0.098 to 
12.50 mg/ml and 0.003 to 100 µg/ml, respectively. To reduce evaporation and 
prevent contamination, the microtitre plate was covered with parafilm and incubated 
at 37 ºC for 24 h. 
 
After incubation, 50 µl of 0.2 mg/ml p-iodonitrotetrazolium chloride (INT; Sigma-
Aldrich, Germany) was added to the wells of the microtitre plate and incubated 
further for 1 h at 37 ºC. Active microorganisms biologically reduce the colourless INT 
to a pink-red colour (McGAW et al., 2007). No colour change showed that inhibition 
had occurred and the concentration of the lowest clear well was recorded as the MIC 
value of the plant extract. The experiments were performed in duplicate and 
repeated independently three times. 
 
4.2.4 In vitro antifungal bioassay 
 
The microplate dilution technique (ELOFF, 1998a) as modified for the antifungal 
assay (MASOKO et al., 2007) with slight modifications (MOTSEI et al., 2003) was 
used in plant extract antifungal activity determination. Both the MIC and minimum 
fungicidal concentration (MFC) values were determined. 
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An overnight (18 h) C. albicans culture was prepared by inoculating a colony of  
C. albicans from the cultured YM plate into 5 ml of sterilized Yeast Malt (YM) broth 
(Sigma-Aldrich, Germany) in a sterile McCartney bottle and incubated at 37 °C in a 
water bath with an orbital shaker. For the in vitro bioassay, 400 µl of the overnight 
fungal culture was diluted with 4 ml of sterile saline solution (0.85% NaCl) in a 
sterilized McCartney bottle. The absorbance of the mixture was determined using a 
UV-visible spectrophotometer at 530 nm. This absorbance was adjusted with sterile 
saline solution to match a 0.5 McFarland standard solution at a range of 0.2500 to 
0.2800. From the prepared culture, a 1:1000 dilution with sterile YM broth was made 
to obtain a concentration of 5 x l05 CFU/ml. 
 
Sterile water (100 µl) was added to each well in a 96-well microtitre plate (Greiner 
Bio-one GmbH, Germany). From the redissolved plant extracts (50 mg/ml), aliquots 
of 100 µl were added to the first well microtitre plate (row A) and diluted two-fold 
serially (column 1-12 downward: A to H). Amphotericin B (0.25 mg/ml; Sigma-
Aldrich, Germany) was prepared as the reference drug and aliquot (100 µl) was 
diluted two-fold serially. From the prepared culture, aliquots of 100 µl were added to 
the wells of the microtitre plate. DMSO, sterile water, fungal-free YM broth and    
C. albicans culture were included as controls. This gave a final concentration ranging 
from 0.098 to 12.50 mg/ml for the plant extracts and 4.80 to 62.50 µg/ml for 
Amphotericin B. The mixture in the microtitre plate was covered with parafilm to limit 
evaporation and prevent contamination. 
 
The microtitre plate was incubated overnight at 37 ºC after which 50 µl of 0.02 mg/ml 
p-iodonitrotetrazolium chloride (INT) was added as a fungal growth indicator. The 
plant extract MIC values were recorded as the concentration of the lowest well 
without colour change after 48 h and growth was indicated by the reddish-pink 
colour. Furthermore, MFC values were determined by adding sterile YM broth (50 µl) 
to all clear wells then incubated for another 24 h at 37 ºC. The extract MFC values 
were recorded as the concentration in the lowest wells of the microtitre plate in which 
there was no colour change. Extracts were screened in duplicate and the experiment 
was performed three times. 
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4.3 Results and discussion 
 
The extract MIC values (antibacterial and antifungal) and MFC values (antifungal) in 
the bioassay are presented in Table 4.1. A total of 80 extracts from the 11 plants 
were screened for their antimicrobial activity. The plant extract evaluation was 
quantified in terms of the MIC required for inhibition of the test microorganism 
(bacteria and fungus) growth as well as the extract‟s lethal effect (MFC) against the 
test fungus in the in vitro bioassay. The MIC is defined as the extract‟s lowest 
concentration that produces an almost complete microbial growth inhibition in a liquid 
culture while MFC is defined as the extract‟s lowest concentration that completely 
causes the death of the test fungus in the in vitro bioassay. 
 
4.3.1 Antibacterial activity of the investigated plant extracts 
 
From the evaluation, most investigated plant species showed some activity at the 
maximum screening concentration (12.50 mg/ml) against one of the test bacteria, 
with the exception of water extracts of C. orbiculata (var. orbiculata and dactylopsis) 
leaves and stems. As indicated in Table 4.1, extract MIC values ranged from  
0.025 to 12.50 mg/ml with MIC values greater than 12.50 mg/ml considered as not 
active in this study. 
 
As presented in Figure 4.1, twenty five (31%) extracts had antibacterial MIC values 
less than 1 mg/ml. From the four extracting solvents, more ethanol extracts had 
noteworthy antibacterial activity while water extracts were the least active. Gram-
negative bacteria were more resistant to the plant extracts than the Gram-positive 
bacteria. Generally, S. aureus was the most susceptible while E. coli was the most 
resistant bacteria to the plant extracts tested. Using an MIC value of less than  
1 mg/ml as the benchmark of noteworthy antibacterial activity (ALIGIANNIS et al., 
2001; KATERERE and ELOFF, 2008), seven extracts exhibited a broad spectrum of 
activity, three extracts were active against Gram-negative bacteria and 13 extracts 




Table 4.1: Antimicrobial activity (MIC) of plant extracts determined using the microplate dilution techniques in in vitro bioassays. 




















 Candida albicans 








































  DCM 3.13 3.13 3.13 1.56 3.13 6.25 
  EtOH 6.25 3.13 3.13 1.56 6.25 6.25 
  Water 12.50 6.25 6.25 6.25 12.50 >12.50 
 Twigs PE 6.25 6.25 3.13 3.13 6.25 6.25 
  DCM 3.13 3.13 3.13 3.13 6.25 6.25 
  EtOH 6.25 6.25 6.25 3.13 6.25 6.26 



















  DCM 1.56 3.13 3.13 0.78 3.13 3.13 
  EtOH 1.56 1.56 3.13 0.78 3.13 6.25 
  Water >12.50 12.50 6.25 >12.50 >12.50 >12.50 
 Stems PE 3.13 1.56 3.13 3.13 3.13 3.13 
  DCM 6.25 6.25 6.25 3.13 3.13 3.13 
  EtOH 0.78 1.56 3.13 3.13 3.13 3.13 






































 Candida albicans 








































var. dactylopsis  DCM 3.13 1.56 3.13 3.13 6.25 6.25 
  EtOH 1.56 1.56 1.56 3.13 6.25 6.25 
  Water >12.50 >12.50 >12.50 >12.50 >12.50 >12.50 
 Stems PE 6.25 3.13 3.13 3.13 6.25 6.25 
  DCM 6.25 3.13 3.13 3.13 3.13 6.25 
  EtOH 6.25 3.13 3.13 3.13 6.25 6.25 
  Water >12.50 >12.50 >12.50 >12.50 >12.50 >12.50 
 

















var. orbiculata  DCM 3.13 1.56 3.13 3.13 6.25 6.25 
  EtOH 1.56 1.56 1.56 3.13 6.25 6.25 
  Water >12.50 >12.50 >12.50 >12.50 >12.50 >12.50 
 Stems PE 6.25 3.13 3.13 3.13 6.25 6.25 
  DCM 6.25 3.13 3.13 3.13 3.13 6.25 
  EtOH 6.25 3.13 3.13 3.13 6.25 6.25 



















  DCM 3.13 3.13 3.13 3.13 3.13 6.25 
  EtOH 3.13 3.13 3.13 3.13 6.25 6.25 
  Water 12.50 3.13 3.13 6.25 6.25 >12.50 
         




















 Candida albicans 








































  DCM 1.56 1.56 3.13 3.13 1.56 3.13 
  EtOH 1.56 0.39 3.13 3.13 6.25 6.25 



















  DCM 1.56 1.56 1.56 1.56 6.25 6.25 
  EtOH 0.78 0.78 3.13 3.13 12.50 >12.50 
  Water >12.50 12.50 >12.50 >12.50 1.56 3.13 
 Stems PE 0.78 0.78 3.13 3.13 6.25 6.25 
  DCM 0.78 1.56 1.56 1.56 6.25 6.25 
  EtOH 1.56 1.56 3.13 3.13 12.50 >12.50 



















  DCM 0.78 0.78 1.56 1.56 1.56 6.25 
  EtOH 0.78 0.78 1.56 0.78 6.25 12.50 
  Water >12.50 12.50 6.25 12.50 12.50 >12.50 
 Corms PE 6.25 6.25 6.25 6.25 6.25 >12.50 
  DCM 6.25 3.13 6.25 3.13 6.25 6.25 
  EtOH 3.13 3.13 6.25 3.13 6.25 6.25 
  Water 1.56 3.13 6.25 3.13 12.50 >12.50 
         




















 Candida albicans 








































  DCM 0.78 0.78 1.56 3.13 1.56 6.25 
  EtOH 3.13 1.56 3.13 1.56 1.56 3.13 
  Water >12.50 3.13 3.13 3.13 >12.50 >12.50 
 Corms PE 3.13 3.13 6.25 3.13 6.25 12.50 
  DCM 3.13 1.56 6.25 3.13 6.25 12.50 
  EtOH 3.13 3.13 6.25 6.25 6.25 6.25 



















  DCM 0.098 0.025 0.39 0.39 3.13 3.13 
  EtOH 0.098 0.195 0.39 0.39 6.25 6.25 
  Water 0.78 1.56 3.13 3.13 12.50 >12.50 
 Stems PE 0.39 0.39 1.56 0.78 3.13 6.25 
  DCM 0.78 0.78 1.56 1.56 6.25 6.25 
  EtOH 0.78 0.78 1.56 1.56 6.25 6.25 



















  DCM 1.56 0.78 1.56 0.78 3.13 6.25 
  EtOH 3.13 1.56 0.78 0.78 3.13 6.25 
  Water >12.50 3.13 >12.50 3.13 0.78 1.56 
         




















 Candida albicans 








































  DCM 3.13 0.78 3.13 1.56 1.56 3.13 
  EtOH 0.39 0.39 0.78 0.39 1.56 1.56 





































Table 4.1: continued... 
 
a
MIC = Minimum inhibitory concentration         
b
MFC = Minimum fungicidal concentration          
c
Extract: PE = Petroleum ether, DCM = Dichloromethane, EtOH = Ethanol 
d
Bacteria: B.s. = Bacillus subtilis, S.a. = Staphylococcus aureus, E.c. = Escherichia coli and K.p. = Klebsiella pneumoniae 
























MIC < 1 mg/ml 















Figure 4.1: Percentage of extracts showing (A) antibacterial and antifungal MIC 
levels (MIC < 1 mg/ml = noteworthy and MIC > 1 mg/ml = non-significant) and     
(B) extracting solvents with noteworthy MIC (MIC < 1 mg/ml) in the antimicrobial 
bioassay. PE = Petroleum ether, DCM = Dichloromethane, EtOH = Ethanol,       




At least one of the four solvent extracts of L. sericea (leaves and stems) had an MIC 
values less than 1 mg/ml demonstrating noteworthy antimicrobial activity against the 
four test bacteria. The best antibacterial inhibitory activity of 0.025 mg/ml was 
exhibited by the PE and DCM extracts of L. sericea (leaves) against B. subtilis and 
S. aureus, respectively. Pharmacological and phytochemical studies on this plant are 
limited and it is the only species in the genus Leucosidea (BOSMAN et al., 2004). 
Further investigation for the possible isolation of bioactive compound(s) will be 
necessary. 
 
Besides the water extract of L. sericea leaves (MIC: 0.78 mg/ml against B. subtilis), 
no other investigated water extracts had any noteworthy antibacterial activity. 
Generally, water extracts exhibit poor or non-detectable antibacterial activity in most 
antimicrobial studies (RABE and VAN STADEN, 1997; FAWOLE et al., 2009a). 
However, a few studies have reported good antibacterial activity in some plant water 
extracts (BUWA and VAN STADEN, 2006; MULAUDZI et al., 2009). The water 
extracts may have dose-dependant antibacterial activity or be effective against other 
pathogenic microbial species/strains not included in this screening (SHALE et al., 
1999). In contrast, ethanol extracts were more active with ten (40%) extracts  
(Figure 4.1) having an MIC less than 1 mg/ml. An investigation of South Africa 
remedies used against various infections showed that ethanol extracts more 
compounds from plant material and possess better antibacterial activity than water 
extracts (JÄGER, 2003). In addition, some traditional medicinal plant remedies are 
prepared using alcohol (ethanol) for rapid results (SPARG et al., 2000). Although 
water is more polar and provided higher yields (see Table 2.2) than ethanol, 
ethanolic extracts showed better antimicrobial activity (Figure 4.1). This was 
probably due to greater affinity of bioactive compound(s) in the plant materials to 
ethanol during extraction. Likewise, TAYLOR and VAN STADEN (2001) observed 
that ethanol has a better affinity for lipophilic compounds from plant material. 
 
The ethanol extract of H. colchicifolia leaves exhibited broad spectrum antibacterial 
activity, although no noteworthy activity was detected in extracts of the corms. 
Likewise, the DCM extract of H. hemerocallidea leaves was active against the Gram-
positive bacteria (B. subtilis and S. aureus; MIC < 1 mg/ml). Although the corm 
extracts of the Hypoxis species showed no noteworthy antibacterial inhibition, 
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antibacterial activity of the ethanol extract of H. hemerocallidea corms against E. coli 
grown on blood plates has been reported (STEENKAMP et al., 2006). Also, a 
previous study on H. hemerocallidea showed antimicrobial activity of the leaves, 
suggesting possible phytochemical similarity in corms and leaves (KATERERE and 
ELOFF, 2008). Consequently, the leaf extracts of Hypoxis species that exhibited 
noteworthy antibacterial activity justifies the need to further investigate alternative 
plant parts, especially the leaves for possible similar pharmacological activity. In 
addition, the use of leaves for treatment of infections enhance the conservation of 
the plant, particularly the endangered species that are extensively harvested 
(ZSCHOCKE et al., 2000; LEWU et al., 2006). 
 
The ethanol extract of S. petersiana leaves showed broad spectrum of antibacterial 
inhibitory activity with MIC less than 1 mg/ml. The ethanol extract of S. petersiana 
seeds has been reported to possess broad spectrum of antibacterial activity and 
luteolin was isolated from the seeds (TSHIKALANGE et al., 2005). Previous work by     
SATO et al. (2000) had also demonstrated the antibacterial activity of luteolin. The 
presence of this compound in the leaves of S. petersiana cannot be ruled out and 
may possibly be responsible for the observed antimicrobial activity in the present 
investigation. 
 
The organic solvent extracts (PE, DCM and EtOH) of C. dregei roots as well as    
F. erigeroides leaves and stems displayed noteworthy antibacterial activity against 
the Gram positive bacteria (B. subtilis and S. aureus). SALIE et al. (1996) reported 
the antibacterial activity of methanol extract of F. erigeroides leaves against 
Pseudomonas aeruginosa and detected the presence of secondary metabolites such 
as flavonoids and saponins. Flavonoids have been reported to exhibit diverse 
pharmacological activities such as antibacterial and anti-inflammatory activity 
(CROZIER et al., 2006). The presence of flavonoids probably accounted for the 
observed antimicrobial activity in this study. 
 
The most susceptible bacterium was S. aureus while E. coli was the most resistant 
as shown in Figure 4.2. The presence of unique lipopolysaccharides on the outer 
membrane of Gram-negative bacteria makes them impermeable to most 
antibacterial compounds (CLEMENTS et al., 2002). This can explain the low number 
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of active plant extracts against E. coli and K. pneumoniae. The observed trend is in 
agreement with previous research findings by various workers (LIN et al., 1999; 
TSHIKALANGE et al., 2005; AMOO et al., 2009b). Gram-negative bacteria 
however, are responsible for most infectious diseases such as gastro-intestinal 
disorder (dysentery and diarrhoeal) and continue to be a serious health problem 
globally (SLEIGH and TIMBURG, 1998). Therefore, selective Gram-negative 
bacteria inhibitory activity exhibited by the leaf extracts of C. myricoides (DCM and 
EtOH) and O. basilicum (EtOH) was noteworthy (MIC values < 1 mg/ml) and 
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Figure 4.2: Bacterial susceptibility to the investigated plant extracts at an MIC value 
of less than 1 mg/ml. B.s. = Bacillus subtilis, S.a. = Staphylococcus aureus,  




4.3.2 Antifungal activity of the investigated plant extracts 
 
A total of 80 plant extracts were screened and 71 extracts inhibited C. albicans 
growth with MIC values ranging from 0.78 to 12.50 mg/ml (see Table 4.1). Although 
89% of the extracts showed some level of fungistatic activity at various 
concentrations tested, generally, majority of the plant extracts exhibited rather weak 
antifungal inhibitory activity. A total of 60 extracts (75%) exhibited varying levels of 
fungicidal effects on C. albicans with MFC values ranging from 0.78 to 12.50 mg/ml. 
Only 20 extracts (25%) showed no fungicidal activity at the highest screening 
concentration (12.50 mg/ml) in the bioassay. 
 
As shown in Figure 4.1, only two extracts (2.5%) had MIC values less than 1 mg/ml 
and are considered as having noteworthy antifungal activity. The PE extract of    
H. colchicifolia leaves exhibited both fungistatic and fungicidal activity. Also, the 
water extract of O. basilicum leaves had an MIC value of 0.78 mg/ml against the test 
fungal strain. Previous studies on O. basilicum revealed its antimicrobial activity 
which was attributed to the presences of phenolic and aromatic compounds 
(GUTIERREZ et al., 2008; HUSSAIN et al., 2008b). 
 
The plants investigated were selected based on their ethnobotanical usage as 
anthelmintics and probably accounted for the relatively lower number of plant 
extracts with noteworthy antifungal activity (MIC/MFC < 1 mg/ml). Also, pathogenic 
fungi infection are more resistant to most therapies used against other infections 
such as bacteria (SLEIGH and TIMBURG, 1998). Antifungal activity screening of 
plant extracts by other workers also showed that pathogenic fungi are quite resistant 
to most plant extracts (MOTSEI et al., 2003; BUWA and VAN STADEN, 2006). 
Furthermore, factors such as low concentration of bioactive compound(s), 
antagonistic effects of other compound(s), and susceptibility of the test fungal strain 







Due to the immune-suppressing activity of helminth infection, leading to the 
development of microbial diseases, and the importance of investigating medicinal 
plants for potential pharmacological activities, the plant extracts were screened for 
antimicrobial activity. Eight plant species exhibited noteworthy antimicrobial activity. 
Extracts from L. sericea had the best antibacterial activity in this study. It exhibited 
broad spectrum antibacterial activity with the lowest MIC value of  
0.025 mg/ml against B. subtilis and S. aureus. H. colchicifolia and O. basilicum were 
the only plant species with noteworthy antifungal activity both having an MIC value of 
0.78 mg/ml. General, ethanol extracts had best antimicrobial activity while the water 
extracts showed low or no antimicrobial activity at the various concentrations tested. 
 
Considering that the plants were selected based on their recorded anthelmintic 
ethnobotanical usage, the antimicrobial activity of the plant extracts was remarkable. 
These results further justify the validity of investigating plant extracts in a variety of  
in vitro bioassays, especially during preliminary tests, because plants contain 
numerous chemicals with potential pharmacological activity. Further investigation 
using in vivo bioassay as well as determining the safety of the active plant extracts 
will also be necessary for valid conclusion to be reached on their potential as 










Cyclooxygenase (COX) enzymes catalyse the conversion of arachidonic acid to any 
of the three main groups of prostanoids namely: prostaglandins, prostacyclins, and 
thromboxanes, which are involved in inflammatory responses (DuBOIS et al., 1998; 
KAM and SO, 2009). Inflammation is a localized protective reaction of body cells or 
tissues in response to physical trauma, chemical irritations such as acids, ultraviolet 
radiations and burns as well as infections caused by bacteria and parasites 
(IWALEWA et al., 2007). Generally, inflammatory processes are complex, involving 
a variety of enzyme activation, chemical mediator release, tissue breakdown and 
repair (VANE and BOTTING, 1995; FERRERO-MILIANI et al., 2007). Lipoxygenase 
(LOX) is also capable of metabolizing arachidonic acid to produce leukotrienes in an 
alternative pathway (SVEINBJÖRNSSON et al., 2008). The LOX pathway is equally 
important because the inhibition of leukotriene synthesis prevents inflammation that 
causes asthma and bronchitis (CELOTTI and LAUFER, 2001). 
 
Parasitic infections such as helminthiasis are associated with gastrointestinal 
inflammation and exhibits various symptoms such as abdominal pain, heat and 
swelling (PARHAM, 2000). In many infected hosts, parasitism may lead to severe 
immuno-pathological complications such as granulomatous disease and organ 
failure (MAIZELS and YAZDANBAKHSH, 2003). In addition, it has been established 
that a number of parasitic organisms produce prostaglandins in the same way as 
their mammalian hosts, and by similar enzymatic mechanisms (BELLEY and 
CHADEE, 1995). This probably accounts for the pathogenesis of many parasitic 
diseases (LIU and WELLER, 1990; BELLEY and CHADEE, 1995). Many plants 
traditionally used as medicines have been shown to posses multi-pharmacological 
activity and most disease states occur with multiple symptoms 
(LAUPATTARAKASEM et al., 2003; HOUGHTON et al., 2007). 
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5.1.1 Overview of inflammation 
 
The occurrence of inflammatory diseases is increasing and affecting more people in 
both developed and developing countries (JÄGER and VAN STADEN, 2005). 
Inflammatory responses are major contributing factors to the exacerbation of many 
disease states such as arthritis, asthma and cardiovascular disease that constitute a 
serious health problem globally (CARRETERO et al., 2008). Inflammation arises as 
a result of an organism attempting to remove injurious stimuli, as well as to initiate 
the healing process of infected cells and tissues (FERRERO-MILIANI et al., 2007). 
These are classified as either acute or chronic. Acute inflammation is characterized 
by rapid onset and short duration involving exudation of fluids and plasma proteins to 
the infected area. Chronic inflammation has a delayed response and prolonged 
duration with the presence of lymphocytes and macrophages leads to fibrosis and 
tissue necrosis (IWALEWA et al., 2007). 
 
During inflammation, arachidonic acid is released from cell membranes by 
phospholipase A2 (PLA2) under stimulation (SCOTT et al., 1999). Once released, 
arachidonic acid is initially oxygenated by COX or LOX to form unstable intermediate 
prostanoids (by inserting molecular oxygen at carbon 5) and finally catalysed by 
COX or LOX enzyme to form the eicosanoid products (BELLEY and CHADEE, 
1995). Chemical mediators such as prostaglandins (PG), nitric oxide (NO), cytokines 
and leukotrienes (LK) are released from mast cells, platelets, neutrophils and 
macrophages or as plasma proteins. They bind to specific target receptors on the 
stimulated cells and tissues, and may increase vascular permeability, promote 
neutrophil chemotaxis, stimulate smooth muscle contraction, increase direct 
enzymatic activity, induce pain and mediate oxidative damage (COLEMAN, 2002). 
During cyclooxygenase reaction, two molecules of oxygen are added to arachidonic 
acid, forming a bicyclic endoperoxide with a further hydroperoxy group in position 15 
that leads to the formation of an intermediate prostaglandin G2 (PGG2). The 
hydroperoxide is then reduced by a functionally coupled peroxidase reaction to form 
prostaglandin H2 (PGH2), an unstable intermediate from which all other prostanoids 
are derived by a variety of enzymatic reactions (SMITH and SONG, 2002). 
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Chemical mediators are also referred to as pro-inflammatory fundamental factors 
because they determine the severity of inflammation based on the duration of the 
inflammatory stimulants. The release of some of the cytokines such as Interleukin 
(IL) -3 ,-4, -5, -6, -10, -13 act as anti-inflammatory mediators within the cells and are 
beneficial to the body (ESCH and STEFANO, 2002). Cytokines such as IL-17A and 
IL-7F significantly contribute to psoriasis in humans (TRIGONA et al., 2009). In view 
of the beneficial and detrimental activity of these chemical mediators, they present 
an important pathway target through which body inflammatory disorders can be 
eradicated or ameliorated (ESCH and STEFANO, 2002; YEDGAR et al., 2007). 
 
5.1.2  Cyclooxygenase (COX) enzymes 
 
COX enzyme is also known as prostaglandin endoperoxide synthase (PGHS). It is 
the main enzyme involved in the production of prostaglandins from the substrate 
arachidonic acid (KAM and SO, 2009). Two distinct isoforms have been identified 
namely: COX-1 and COX-2. In 2002, a splice variant of COX-1 was discovered in 
canine brain cells and given various names such as COX-3, COX-1b or COX-1v 
(BOTTING, 2006; KAM and SO, 2009). Due to the important and distinct roles that 
COX-1 and COX-2 enzymes play in inflammatory processes (WILLIAMS and 
DuBOIS, 1996), both enzymes were considered in this investigation. 
 
COX-1 enzyme has a molecular weight of 71 kDa and was first isolated from sheep 
seminal vesicles (HEMLER and LANDS, 1976). This enzyme is present at relatively 
constant levels in many tissues and cells, and is regarded as a “house-keeping” 
gene (CROFFORD, 1997; MORITA, 2002). The COX-1 enzyme concentration 
slightly increases between 2- to 4-fold in response to stimulants such as hormones 
and growth factors (DeWITT, 1991). COX-1 enzyme produces prostaglandins 
involved in the regulation of normal kidney and stomach functions as well as 
vascular homeostasis (KLIMP et al., 2001). It is also present in platelet aiding in 
thromboxane A2 (TXA2) production which prevents inappropriate bleeding (FUNK et 
al., 1991). Consequently, the prostanoids produced by COX-1 are important for the 
maintenance of regular cellular physiological functions (BOTTING, 2006). 
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The COX-2 enzyme has a molecular weight of 71 kDa and was discovered in 1988 
by Daniel Simmons (BOTTING, 2006). During stable conditions, the COX-2 enzyme 
is present in low concentrations in most cells and is regulated by factors such as 
cytokines, intracellular messengers and substrate (arachidonic acid) availability. The 
COX-2 enzyme is particularly responsive to chemical mediators of inflammation 
(MORITA, 2002). This enzyme is a source of prostaglandins in most acute 
inflammation and is mainly present in the nuclear envelope, brain and endoplasmic 
reticulum (VANE et al., 1998). 
 
5.1.3 Treatment of inflammation  
 
Anti-inflammatory refers to the property of a substance or treatment to reduce 
inflammation. Anti-inflammatory agents are categorised into two groups namely: the 
non-steroidal and steroidal or glucocorticoid drugs. The non-steroidal anti-
inflammatory drugs (NSAIDs) have been used by humans in various forms for over 
3500 years (VANE, 2000). The inhibitory activity of NSAIDs is responsible for the 
anti-inflammatory, antipyretic and analgesic properties exhibited by these agents. 
These drugs act by inhibiting the activity of COX enzymes, the rate-limiting step in 
the conversion of arachidonic acid to prostaglandins (VANE and BOTTING, 1995). 
For instance, NSAIDs such as aspirin inhibit COX enzymes by irreversible 
acetylation of serine 530 in the COX-1 active site or serine 516 in the COX-2 active 
site (VAN DER OUDERAA et al., 1980). Glucocorticoids also inhibit the two main 
products (prostaglandins and leukotrienes) of inflammatory processes. These are 
available in most vertebrate animal cells and functions by binding to the 
glucocorticoid receptor (GR). The formation of the GR complex leads to the 
synthesis of anti-inflammatory proteins that block the expression of pro-inflammatory 
proteins in the cytosol (RHEN and CIDLOWSKI, 2005). 
 
Both steroidal and non-steroidal anti-inflammatory chemotherapy presently used in 
treatment of inflammation have various limitations (CARRETERO et al., 2008). For 
instance, steroids such as prednisone, prednisolone, and hydrocortisone which are 
naturally secreted by the adrenal glands or can be chemically synthesized are 
associated with side effects such as immunosuppression, muscle breakdown, 
glaucoma, increased blood pressure and retarded growth in children. NSAIDs such 
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as ibuprofen and aspirin have been implicated in gastro-toxicity, anti-thrombotic 
action as well as Reye‟s syndrome in children (WILSON, 1991; BOTTING, 2006). 
 
Studies have shown that medicinal plants potentially provide a useful source of new 
effective anti-inflammatory agents (TAYLOR et al., 2001). Globally, many plants 
have been successfully screened as potential sources of anti-inflammatory agents 
(TUNÓN et al., 1995; LAUPATTARAKASEM et al., 2003; KAILEH et al., 2007; 
MENICHINI et al., 2009). Likewise, many South African medicinal plants have also 
shown promising results as sources of potential anti-inflammatory agents (TAYLOR 
et al., 2001; IWALEWA et al., 2007). Plant secondary metabolites such as 
flavonoids, alkaloids, essential and volatile oils have the tendency to modify activities 
of inflammatory cells (IWALEWA et al., 2007). Prostaglandin synthesis inhibition can 
be evaluated using the COX bioassays, an example of mechanism-based assays 
utilizing sub-cellular structures for inhibition detection (HAMBURGER and 
HOSTETTMANN, 1991). The inhibitory effect of plant extracts against COX enzyme 
as a target of the inflammatory process was evaluated. 
 
5.2 Materials and methods 
 
Extract preparation and the bioassays (COX-1 and -2) were performed as detailed 
below. 
 
5.2.1 Extract preparation  
 
Plant extraction was carried out as described in Section 2.2.2. For each plant 
sample investigated, dried materials were redissolved in 80% ethanol for organic 
solvent extracts (PE, DCM and EtOH) and in water for aqueous extracts. The 
extracts were redissolved at 10 mg/ml with the above mentioned solvents. 
 
5.2.2 Enzyme and substrate preparation 
 
COX-1 and COX-2 enzymes were obtained from Sigma-Aldrich, USA. COX-1 was 
isolated from ram seminal vesicles while human recombinant COX-2 was isolated 
from a Baculovirus over-expression system in Sf 21 cells. The enzyme activity 
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concentration was 5838 units/ml for COX-1 and 625 units/ml for COX-2. The COX 
enzymes were diluted with Tris(hydromethyl)aminomethane (TRIS) storage buffer 
(pH 8.0) (Appendix 3) to obtain 50 µl of 75 units enzyme concentration per aliquot. 
The prepared COX enzymes (50 µl, 75 units) were stored in an ultra-freezer at  
-70 ºC until required. 
 
The substrate 14C-arachidonic acid with a specific activity of 57 mCi/mmol and 
concentration of 0.1 mCi/ml was obtained from Amersham, GE Healthcare, UK. One 
hundred microlitres of the radio-labelled arachidonic acid was diluted with 6.75 µl of 
unlabelled arachidonic acid (Sigma-Aldrich, Germany) to obtain the final 
concentration (16 Ci/mol, 30 µM) required for the bioassay. 
 
5.2.3 In vitro COX-1 inhibitory bioassay  
 
The COX-1 inhibitory activity of the plant extracts was evaluated according to the 
method of WHITE and GLASSMAN (1974) as modified by JÄGER et al. (1996) with 
slight modifications. For the organic extracts, an aliquot of 2.5 µl from the 10 mg/ml 
extract was diluted with 17.5 µl distilled water in Eppendorf tubes while an aliquot of 
20 µl water extracts were added directly to the Eppendorf tubes. The background 
and solvent blanks contained 17.5 µl distilled water and 2.5 µl of 80% ethanol while a 
reference anti-inflammatory drug was prepared by adding 2.5 µl of 200 µM 
indomethacin (Sigma-Aldrich, Germany) with 17.5 µl distilled water. The controls and 
test samples were prepared in duplicate for the bioassay. Thereafter, 10 µl of 2 N 
hydrogen chloride (HCl) was added to the background samples to acidify the solution 
and denature the enzymes. 
 
A co-factor solution was prepared by adding 3 mg L-epinephrine (Sigma-Aldrich, 
Germany) and 3 mg reduced glutathione (Sigma-Aldrich, USA) into 10 ml of 0.1 M 
TRIS buffer (pH 8.0). One hundred microlitres hematin solution (Sigma-Aldrich, 
Germany) (Appendix 3) were added to the mixture and maintained on ice. The 
prepared aliquot of 50 µl COX-1 enzyme containing 75 units stored at -70 °C was 
dissolved in 200 µl of 0.1 M TRIS buffer (pH 8.0) (Appendix 3) and activated with 
1250 µl co-factor solution. This resultant solution (1500 µl) was pre-incubated on ice 
at room temperature for 5 min. After incubation, 60 µl of the resultant solution were 
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added to each prepared test extract sample and controls contained in the Eppendorf 
tubes and pre-incubated at room temperature for 5 min. 
 
The reaction substrate was prepared by mixing 5 µl of 14C-arachidonic acid  
(16 Ci/mol, 30 µM), 5 µl of 0.2% Na2CO3 and 490 µl of 0.1 M phosphate buffer  
(pH 7.4) (Appendix 3). Thereafter, the enzymatic reaction was initiated by adding  
20 µl of the prepared arachidonic acid (substrate) solution into the enzyme-sample 
as well as the controls and incubating for 10 min in a water bath at 37 ºC. The final 
concentrations in the bioassay were 250 µg/ml for the organic solvent extracts and  
2 mg/ml for aqueous extracts while the indomethacin was at a final concentration of 
5 μM. Each test solution contained 3 units of COX-1 enzyme and 6 µM of the 
arachidonic acid in the final volume. After incubation, the reaction was terminated by 
adding 10 µl of 2N HCl to all the reaction tubes with the exception of background test 
samples. Following this, 4 µl of 0.2 mg/ml unlabelled prostaglandins (PGE2:PGF2α 
1:1) (Sigma-Aldrich, Germany) and 1 ml of hexane:1,4-dioxan:acetic acid at a ratio of 
70:30:0.2 (v/v/v) was added to each sample. 
 
Prostaglandins and unmetabolized arachidonic acid were separated by column 
chromatography over silica gel. The silica columns were prepared by packing silica 
gel 60 (Merck, Germany) with particle size of 0.063-0.200 mm in hexane:1,4-
dioxan:acetic acid (70:30:0.2 v/v/v) mixture into Pasteur pipettes reaching a height of 
3 cm and stopped at the base with glass wool. The test solutions were applied to 
individual Pasteur pipettes and the unmetabolized arachidonic acid was eluted with  
4 ml of hexane:1,4-dioxan:acetic acid (1 ml added at a time). The prostaglandin 
products were eluted with 3 ml ethyl acetate:methanol (85:15 v/v) and collected from 
each column into individual scintillation vials. Scintillation fluid (4 ml) (Beckman 
CoulterTM, USA) was added to the eluate in the scintillation vials and the radioactivity 
of resultant cocktail was measured using a Multi Purpose Scintillation Counter 
(Beckman CoulterTM LS 6500, USA). The experiment was repeated twice and 
replicates of each test solution were used for each experiment. The percentage of 
prostaglandin synthesis inhibition by the plant extracts were evaluated by comparing 
the amount of radioactivity present in the sample to that in the solvent blank and 
background samples using the equation given below: 
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COX inhibition  %  =  1 –  
 DPMextract  –  DPMbackground  
 DPMsolvent blank  – DPMbackground  
   × 100 
 
where DPM = disintegrations per minute; solvent blank = 17.5 µl water + 2.5 µl EtOH 
(80%); background = 17.5 µl water + 2.5 µl EtOH (80%) with the added COX 
enzyme inactivated by HCl before the addition of arachidonic acid (substrate). 
 
5.2.4 In vitro COX-2 inhibitory bioassay 
 
A similar experimental protocol as described for the COX-1 bioassay with slight 
modifications, was used for the COX-2 enzyme (ZSCHOCKE and VAN STADEN, 
2000) The co-factor was prepared by adding 0.3 mg L-epinephrine and 0.6 mg 
reduced glutathione into 10 ml TRIS buffer (pH 8.0), followed by addition of 100 µl 
hematin solution. The reference anti-inflammatory drug was prepared by mixing 2.5 
µl of 8 mM indomethacin and 17.5 µl filtered water which resulted in a final 
concentration of 200 µM in the bioassay. Further technique employed and evaluation 
of inhibition (%) is as described for COX-1 above (Section 5.2.3). 
 
In addition, plant extracts that exhibited an inhibition of 70% and above for COX-2 
enzyme inhibitory activity were further tested at lower extract concentrations of    
5 mg/ml (final concentration: 125 µg/ml) and 2.5 mg/ml (final concentration: 62.5 
µg/ml) against both COX-1 and -2 enzymes as described above (Sections 5.2.2 and 
5.2.3). 
 
5.2.5 Statistical analysis 
 
The level of significant differences in the activity of the investigated plant extracts 
was determined statistically. The statistical analysis was performed using SPSS 
software package for Windows (SPSS® version 10.0, Chicago, USA). Analysis was 
performed within individual extracting solvents and compared at the highest 
screening concentration of 250 µg/ml and 2 mg/ml for organic and water extracts, 
respectively. 
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5.3 Results and discussion 
 
A total of 80 extracts were screened for their ability to inhibit both COX-1 and COX-2 
enzymes. These results were analyzed using a scheme devised by TUNÓN et al. 
(1995) where four levels of inhibitory activity were defined as: below 20% was 
considered “insignificant”, between 20 and 40% was “low” activity, from 40 to 70% 
was “moderate” activity, and above 70% was regarded as “high” inhibition at the 
extract concentration tested. 
 
5.3.1 COX-1 inhibitory activity of the investigated plant extracts 
 
The COX-1 inhibition (%) by the 80 plant extracts are presented in Table 5.1. Based 
on activity level definition (TUNÓN et al., 1995), 46 extracts displayed a high COX-1 
inhibitory activity, 16 extracts exhibited moderate activity, and 7 extracts had low 
activity while for 11 extracts inhibition was considered insignificant. Although, the 
highest COX-1 inhibition (%) was exhibited by the DCM extract of A. oppositifolia 
leaves with 99.98% inhibition, it was not significantly different from inhibition of the 
DCM extracts of Cotyledon species (leaves), C. dregei (roots) F. erigeroides 
(Leaves), Hypoxis species (corms) and L. sericea (leaves and stems). A total of 8 
extracts namely: A. oppositifolia twigs (PE and EtOH), C. myricoides leaves (EtOH 
and water), C. orbiculata var. orbiculata stems (PE), H. colchicifolia corms (EtOH) as 
well as H. hemerocallidea corms and leaves (EtOH) displayed no COX-1 inhibitory 
activity (0%) against the COX-1 enzyme. 
 
Non-polar organic solvent extracts showed higher COX-1 inhibition (%) than the 
polar solvent extracts. The extracting solvents (PE, DCM, EtOH and water) yielded 
20 extracts each which were investigated and a total of 16 DCM and 13 PE extracts 
as well as 11 EtOH extracts exhibited high COX-1 inhibition while only 6 water 
extracts displayed high COX-1 inhibition. Similar COX inhibition investigations have 
shown that non-polar solvent extracts generally possess better COX inhibition than 
water extracts (JÄGER et al., 1996; FAWOLE et al., 2009b). The observed 
inhibitory activity of the non-polar extracts could be attributed to better extraction of 
the active principles by the extracting organic solvents. 
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Table 5.1: COX-1 inhibition (%) of the plant extracts in the COX-1 bioassay which was 
tested at a final concentration of 250 μg/ml and 2 mg/ml for the organic and water 























































































































































































































Mean values in the same column followed by different letter(s) are significantly different (P = 0.05) 
according to Duncan‟s Multiple Range Test. 
Extracting solvents: PE = Petroleum ether, DCM = Dichloromethane and EtOH = Ethanol. 
COX-1 inhibition (%) by indomethacin at final bioassay concentration of 5 µM was 75.50±2.34. 
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Organic solvent extracts of the leaves of A. oppositifolia showed a high COX-1 
enzymes inhibitory activity. Previous screening of some Zulu medicinal plants for 
prostaglandin-synthesis inhibitors yielded a high COX enzyme inhibitory (78%) 
activity for the EtOH extract of A. oppositifolia roots (JÄGER et al., 1996). The 
potential anti-inflammatory activity by the leaf extracts is very important for the 
sustainable harvesting of the plant for medicinal use. A. oppositifolia is a member of 
the family Apocynaceae which are noted for their high alkaloid content accounting for 
their potent pharmacological activity (GURIB-FAKIM, 2006). Likewise, L. sericea is a 
member of the family Rosaceae which are known for a high tannin content. Members 
of this family have been used as remedies for many diseases in traditional medicine 
(TUNÓN et al., 1995). All the extracts of the leaves and stems of L. sericea 
displayed high COX-1 inhibition. IWALEWA et al. (2007) identified alkaloids and 
tannins as examples of plant secondary metabolites with inhibitory activity on the 
molecular targets of pro-inflammatory mediators in inflammatory responses. Thus, 
tannins and alkaloids probably accounted for the observed high COX-1 activity in    
A. oppositifolia and L. sericea extracts tested in this study. 
 
Although ethanol and water extracts of H. hemerocallidea corms displayed no 
significant inhibitory activity in this study, previous studies of both extracts had 
demonstrated promising anti-inflammatory activity both in vitro (JÄGER and VAN 
STADEN, 2005) and in vivo (OJEWOLE, 2006) investigations, respectively. Factors 
such as seasonal variation in chemical composition of plant species (TAYLOR et al., 
2001) as well as the discrepancies that occur between in vitro and in vivo extract 
biological activity (HOUGHTON et al., 2007) are possible reasons for the non-activity 
in H. hemerocallidea corm extracts in this study. 
 
Both water and organic solvent extracts of O. basilicum leaves yielded high to 
moderate COX-1 inhibition. Recent in vitro studies on methanolic extracts of             
O. basilicum demonstrated anti-inflammatory effects by inhibiting the pro-
inflammatory cytokines and mediators in a mitogenic lymptocyte proliferation assay 
(SELVAKKUMAR et al., 2007). Similarly, significant anti-inflammatory activity by the 
extract of O. basilicum have been demonstrated in an in vivo test against 
carrageenan and different other mediator-induced paw oedema in experimental rats 
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(SINGH, 1999). The COX inhibition of O. basilicum in this study further confirms the 
anti-inflammatory activity potentials of the plant extract. 
 
5.3.2 COX-2 inhibitory activity of the investigated plant extracts  
 
The COX-2 inhibition (%) of the 80 plant extracts are presented in Table 5.2. 
According to inhibitory activity definition (TUNÓN et al., 1995), 32 extracts displayed 
high COX-2 inhibitory activity, 22 extracts exhibited moderate inhibitory activity, 10 
extracts had low activity and16 extracts had inhibitory activity that was considered 
insignificant. The most active extract was the DCM extract of F. erigeroides (stems) 
with 99% inhibition. Generally, the inhibitory activity against COX-2 enzyme was 
lower than that of COX-1. This can be attributed to the COX-1 active site being 
smaller than that of COX-2 (MORITA, 2002). Hence, the smaller active site of COX-1 
is more easily inhibited than the larger COX-2 site (BOTTING, 2006). 
 
As observed in the COX-1 bioassay, the non-polar solvent extracts (PE and DCM) 
inhibited the COX-2 enzyme better than the more polar solvent extracts. High COX-2 
inhibition was exhibited by 12 PE and DCM extracts while only 7 EtOH and 1 water 
extracts displayed similar high COX-2 inhibition. A total of 7 had zero COX-2 
inhibition and they were all polar solvent extracts. This observed activity at the low 
screening concentration (250 µg/ml) was noteworthy because lipophilic compounds 
which are extracted by non-polar solvents have better resorption through the cell 
membrane (ZSCHOCKE et al., 2000). Lipophilic compounds are not likely to occur 
in higher concentrations in water extracts (TUNÓN et al., 1995) and are possibly 
responsible for the high number of non-significant as well as the low activity 
displayed by most polar solvent extracts. 
 
As observed with the COX-1 bioassay, non-polar solvent extracts of C. myricoides 
stems had high inhibitory activity against the COX-2 enzyme. Many species of the 
genus Clerodendrum such as C. trichotomum, C. serratum and C. phlomidis have 
been reported to exhibit potent inhibitory effect on pro-inflammatory cytokines such 
as tumor necrosis factor-alpha (TNF-α) and Interleukin-1-beta (IL-1β) responsible for 
various inflammatory conditions (SHRIVASTAVA and PATEL, 2007). 
  
66 
Table 5.2: COX-2 inhibition (%) of the plant extracts in the COX-2 bioassay which was 
tested at a final concentration of 250 μg/ml and 2 mg/ml for the organic and water 
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Mean values in the same column followed by different letter(s) are significantly different (P = 0.05) 
according to Duncan‟s Multiple Range Test. 
Extracting solvents: PE = Petroleum ether, DCM = Dichloromethane and EtOH = Ethanol. 




The in vivo anti-inflammatory activity of the EtOH extract of C. serratum roots has 
also been demonstrated in previous studies (NARAYANAN et al., 1999). Closely 
related plants such as different plant species of the same genus are often known to 
possess the same chemical compounds (JÄGER et al., 1996), the presence of 
similar bioactive compound(s) in these different species in the genus Clerodendrum 
possessing anti-inflammatory potentials cannot be ruled out. This probably 
accounted for the high COX-2 inhibition exhibited by the non-polar extracts of  
C. myricoides stems. 
 
Organic solvent extracts of S. petersiana exhibited high to moderate COX-2 enzyme 
inhibition activity. Studies by TSHIKALANGE et al. (2005) reported the presence of 
luteolin in S. petersiana which was subsequently isolated from the seeds. Flavonoids 
particularly luteolin have been reported to inhibit pro-inflammatory enzymes which 
probably contribute to their anti-inflammatory activity (LÓPEZ-LÁZARO, 2009). 
According to JÄGER et al. (1996), a species containing a known anti-inflammatory 
compound has the potential to inhibit inflammatory processes. The presence of 
flavonoids such as luteolin in S. petersiana probably accounted for the high COX-2 
inhibitory activity observed in the DCM extract of this species. 
 
The high to moderate inhibitory activity exhibited by most leaf extracts against  
COX-2 inhibition is important for conservation of medicinal plant species. For 
example, extracts from the leaves of plant species such as H. colchicifolia and  
C. dregei exhibited better COX-2 inhibition activity than the underground parts. 
Leaves can be harvested sustainably while utilizing these plants as medicine without 
the inherent survival threat associated with destructive harvesting of underground 
parts such as corms and roots. This observed high COX-2 inhibitory activity of the 
leaf extracts was in line with the suggestion for the need to investigate non-
destructive medicinal plant parts for possible noteworthy similar pharmacological 
activity as present in the underground parts (ZSCHOCKE et al., 2000). 
 
A high number of extracts inhibited both the COX-1 and -2 enzymes. This denotes 
the potentials of these extracts to reduce inflammation, and they are probably 
employed in traditional medicine to reduce pain which is associated with helminth 
infections. Traditional medicine lack scientific investigations to determine the cause 
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of diseases, as a result, the common symptoms that are observed provide a clue on 
plant material used and other treatment regimes employed (HEWSON, 1998). 
 
5.3.3 Dose responses of plant extracts in COX-1 and -2 bioassays  
 
The COX percentage inhibition in both COX-1 and COX-2 bioassays of the extracts 
at three concentrations are depicted in Figures 5.1 and 5.2, respectively. The dose 
responses of the only water extract (C. dregei roots) with high (> 70%) COX-2 
inhibition at maximum screening was not included in the figures. Water extracts were 
screened at 2, 1 and 0.5 mg/ml and C. dregei water displayed 84, 59 and 30%  
COX-1 inhibition while COX-2 was 70, 50 and 0%. Generally, a dose-dependant 
inhibitory activity was exhibited by the plant extracts. A similar trend was reported for 
the anti-inflammatory investigation of twelve medicinal plants used against gastro-
intestinal ailments in South Africa (FAWOLE et al., 2009b). 
 
Apart from F. erigeroides leaves and stems, and L. sericea leaves, all PE extracts 
exhibited a dose-dependant COX-1 enzyme inhibitory activity as depicted in    
Figure 5.1 (A). For the DCM extracts, S. petersiana (leaves) and C. dregei (roots) 
had approximately the same level of COX-1 inhibition regardless of the extract 
concentration. All the other DCM extracts were dose-dependant as shown in  
Figure 5.1 (B). The COX-1 inhibition of the ethanol extracts varied with changes in 
concentration of extracts as depicted in Figure 5.1 (C). 
 
In the COX-2 bioassay, with the exception of the DCM extract of S. petersiana 
(leaves), all other extracts exhibited a dose-dependant COX-2 inhibitory activity as 
shown in Figure 5.2. At the lowest concentration (62.5 µg/ml) assayed, only five 
extracts namely: leaves of C. orbiculata var. dactylopsis (EtOH), H. colchicifolia (PE), 







































A.o. C.o. F.e. H.c. L.s. O.b. C.m. F.e. L.s. C.d.H.h.H.c.
Leaves Stems RootsA
A.o. C.o. C.o.* F.e. L.s. S.p. A.o. C.m. F.e. L.s. H.c. C.d.
B Leaves Stems Corms Roots
Leaves StemsC
C.o.* C.d. H.c. O.b. C.o. F.e. L.s.
 
Figure 5.1: COX-1 inhibitory activity (%) at three concentrations of the plant extracts 
that had high (> 70%) COX-2 inhibition at the highest screening concentration; (A) 
petroleum ether, (B) dichloromethane and (C) ethanol extracts. COX-1 inhibition (%) 
of indomethacin was 78.50±3.38. 
A.o. - Acokanthera oppositifolia, C.m. - Clerodendrum myricoides, C.o. - Cotyledon orbiculata var. 
orbiculata, C.o.* - Cotyledon orbiculata var. dactylopsis, C.d. - Cyathea dregei, F.e. - Felicia 
erigeroides, H.c. - Hypoxis colchicifolia, H.h. - Hypoxis hemerocallidea, L.s. - Leucosidea sericea, O.b. 





































A.o. C.o. F.e. H.c. L.s. O.b. C.m. F.e. L.s. C.d.H.h.H.c.
Leaves Stems RootsA
A.o. C.o. C.o.* F.e. L.s. S.p. A.o. C.m. F.e. L.s. H.c. C.d.
B Leaves Stems Corms Roots
Leaves StemsC
C.o.* C.d. H.c. O.b. C.o. F.e. L.s.
 
Figure 5.2: COX-2 inhibitory activity (%) at three concentrations of the plant extracts 
that had high (> 70%) COX-2 inhibition at the highest screening concentration; (A) 
petroleum ether, (B) dichloromethane and (C) ethanol extracts. COX-2 inhibition (%) 
of indomethacin was 65.10±3.54. 
A.o. - Acokanthera oppositifolia, C.m. - Clerodendrum myricoides, C.o. - Cotyledon orbiculata var. 
orbiculata, C.o.* - Cotyledon orbiculata var. dactylopsis, C.d. - Cyathea dregei, F.e. - Felicia 
erigeroides, H.c. - Hypoxis colchicifolia, H.h. - Hypoxis hemerocallidea, L.s. - Leucosidea sericea,  




Generally, the extracts inhibited the COX-1 enzyme better than the COX-2. The  
non-polar extracts were more active than polar extracts for both enzymes. Organic 
solvent extracts of A. oppositifolia leaves, C. orbiculata var. dactylopsis leaves,  
C. dregei leaves and roots, F. erigeroides leaves, H. hemerocallidea corms,    
L. sericea leaves and stems, O. basilicum leaves and S. petersiana leaves had three 
or more extracts inhibiting COX-1 by greater than 70% in the COX-1 bioassay. 
Similar high COX-2 percentage inhibition was obtained for organic solvent extracts of  
C. dregei roots, F. erigeroides stems, and L. sericea stems in the COX-2 bioassay. 
 
The inhibitory activity of most extracts were dose dependent as lower activity was 
observed at lower extract concentrations. Organic solvent extracts of C. dregei roots,          
F. erigeroides leaves and stems as well as L. sericea leaves and stems showed the 
most promising COX inhibitory activity. Further investigations will be required to 
eliminate the possibility of false positive results by these extracts. The removal of 
tannins from the plants might be necessary as these compounds are known to 
denature or destroy the enzymes (TUNÓN et al., 1995). 
 
COX-2 inhibition is attributed with fewer side effects and is important for 
inflammation treatment associated with many diseases (MORITA, 2002; BOTTING, 
2006). Hence, possible isolation and identification of active compounds of plant 
species such as F. erigeroides, L. sericea and O. basilicum that exhibited significant 
inhibitory activity against the COX-2 enzyme will be necessary. Inflammation is a 
complex process that involves other enzymes and reactions (VANE and BOTTING, 
1998). Thus, the COX enzymes inhibition by the plant extracts give an indication of 
the anti-inflammatory potentials of the plant. The effectiveness of these species and 
isolated compound(s) against other enzymes such as LOX involved in the LOX 
pathway during the inflammatory syndrome also requires investigation. 
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Phytochemicals are chemicals that naturally occur in plants (BRIELMANN et al., 
2006). In plants, the metabolic processes can be classified into primary and 
secondary metabolism, which are often interconnected to one another (GURIB-
FAKIM, 2006). Primary metabolites such as phyto-sterols, nucleotides, amino acids 
and organic acids are required for basic life processes (WINK, 2003). In addition, 
plants synthesize and accumulate a vast group of compounds known as secondary 
metabolites that are expressed in terms of ecological and biochemical differentiation 
as well as species diversity (GURIB-FAKIM, 2006; LEWINSOHN and GIJZEN, 
2009). Although, secondary metabolites are mostly present in low quantities and 
have no recognized role in basic life processes such as photosynthesis, and the 
growth and development that are associated with primary metabolites, they are 
mainly involved in the plant‟s interaction and survival in their environment (CROZIER 
et al., 2000; NAMDEO, 2007). The biological roles of most secondary metabolites 
remain obscure (LEWINSOHN and GIJZEN, 2009), however, studies have shown 
that they protect plants against ultra violet radiations, serve as attractants for 
pollinators, and impediments against plant herbivores and pathogens (WINK, 1999; 
DEWICK, 2002). 
 
Plants are characterized by the production of a vast and highly diverse reservoir of 
secondary metabloites (WINK, 2003). Although these chemicals are present in most 
plants, similar metabolites may be found in highly divergent plant groups while others 
may be peculiar to only a species, genus or family. This irregular occurrence and 
chemical variation among plants has been linked to the evolutionary relationship that 
existed between the plants and their associated herbivores and pathogens (NYMAN 
and JULKUNEN-TIITTO, 2005). In addition, the production and accumulation of 
these metabolites are regulated in space and time, as well as being specific to 
certain cells and organelles (WINK, 1999). 
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6.1.1 Medicinal activity of plant secondary metabolites 
 
For centuries, mankind has utilized plant secondary metabolites as dyes, fragrances, 
stimulants, insecticides, vertebrate and human poisons, as well as for their 
therapeutic values (CROZIER et al., 2006). Plants are currently seen as potential 
sources of novel natural drugs and antibiotics (CROZIER et al., 2000; DEWICK, 
2002). Many of the secondary metabolites are biologically active having phyto-
pharmaceutical uses. Pharmaceutically significant secondary metabolites include 
alkaloids, glycosides, flavonoids, volatile oils, tannins and resins (NAMDEO, 2007). 
 
Based on their biosynthetic origins, plant secondary metabolites are broadly divided 
into three major groups, namely phenolics, alkaloids and saponins (steroidal or 
triterpenoid glycosides) (CROZIER et al., 2006). These metabolites have been 
exploited for their therapeutic values in several ways. Characteristics, distribution 




Phenolic compounds are characterized by the presences of at least one aromatic 
ring with one or more hydroxyl groups attached. Phenolics are widely represented in 
the plant kingdom and approximately 8000 phenolic structures have been identified 
(STRACK, 1997). The phenolics, as a group, include flavonoids and other related 
polyphenolic compounds (tannins). Flavonoids are the most common of the 
phenolics occurring throughout the plant kingdom (HARBORNE, 1993). Flavonoids 
are further divided into sub-groups such as flavones, flavonols, flavan-3-ols and 
anthocyanidins (CROZIER et al., 2006). Tannins are common to vascular plants and 
exist primarily within woody tissues, but may also be present in leaves, flowers and 
seeds. Tannins are found either as condensed or hydrolysable forms (BRIELMANN 
et al., 2006). Condensed tannins are the most abundant polyphenols found in many 
plant families and may constitute up to 50% of the dry weight of the leaves (LEVIN, 
1976). Most tannins are extremely astringent rendering plant tissues inedible. Due to 
their astringency, they precipitate or bind to proteins causing detrimental effects in 
the digestive tract of livestock and are referred to as anti-nutritional compounds 
(GITHIORI et al., 2006). 
74 
Pharmacological activities of flavonoids such as anti-inflammatory, antimicrobial, 
antioxidant and anticancer activities have been extensively reported (TAPAS et al., 
2008; LÓPEZ-LÁZARO, 2009). Flavonoids such as hesperidin and rutin are used for 
decreasing capillary fragility, and quercetin is commonly utilized for its anti-diarrhoeal 
property (GURIB-FAKIM, 2006). A recent study also reported the anthelmintic 
activity of flavones isolated from Struthiola argentea (AYERS et al., 2008). The 
medicinal properties of tannins, especially their anti-parasitic activity against gastro-
intestinal nematodes (ATHANASIADOU et al., 2001; HOSTE et al., 2006), 
antimicrobial (AKIYAMA et al., 2001; FUNATOGAWA et al., 2004), as well as 
antioxidant and anti-human-immunodeficiency-virus (HIV) activities (NOTKA et al., 




Saponins are a chemically diverse group widely distributed in over 100 vascular 
plant families (YOSHIKI et al., 1998). Saponins are structurally related compounds 
containing a steroid or triterpenoid aglycone (sapogenin). They are linked to one or 
more oligosaccharide moieties by a glycosidic linkage (MAKKAR et al., 2007). The 
steroidal saponins are mostly found in monocotyledonous angiosperms while 
triterpenoid saponins are mainly associated with dicotyledonous angiosperms 
(BRUNETON, 1999). The presence of both polar (sugar) and non-polar (steroid or 
triterpene) groups is responsible for the strong surface-active properties of saponins 
(MAKKAR et al., 2007). The presence of these groups and the variability of their 
structures as well as the attachment positioning has been studied with respect to the 
physiological, immunological and pharmacological properties of saponins (FRANCIS 
et al., 2002). 
 
Most of the biological potential of saponins is attributed to their action on cell 
membranes as they possess the ability to form pores in membranes resulting in their 
frequent use in physiological research (PLOCK et al., 2001; FRANCIS et al., 2002). 
Saponins have been reported to possess antimicrobial, antioxidant and molluscicidal 




6.1.1.3 Alkaloids  
 
Alkaloids are a diverse group of low molecular weight organic bases containing 
secondary, tertiary or cyclic amines (MAKKAR et al., 2007). As a result, alkaloids 
are highly soluble in most acidic solutions to form water soluble salts. Alkaloids form 
the largest single class of plant secondary metabolites, occurring in approximately 
20% of all plant species (ZULAK et al., 2006; MAKKAR et al., 2007). Many of the 
earliest compounds isolated from plants such as morphine, cocaine and quinine are 
alkaloids. 
 
Many of the approximately 12 000 known alkaloids have been exploited as 
pharmaceuticals, stimulants, narcotics and poisons (WINK, 1998). Plants containing 
alkaloids are well known for their pharmacological activity. Cocaine, morphine, 
quinine and strychnine are examples of plant-derived alkaloids with potent 
pharmacological activity (BRIELMANN et al., 2006). Cocaine, from Erythroxylum 
coca, is used as a local anesthetic and as a potent central nervous system stimulant, 
while strychnine, derived from Strychnos bark, is a nerve stimulant. Papaverine, 
which is obtained from opium, is a smooth muscle relaxant (POLYA, 2003). Nicotine, 
a product from Nicotiana tabacum, is used as a powerful insecticide, while quinine, 
which was isolated from the bark of Cinchona species, as well as artemisinin, 
obtained from Artemisia annua are well known anti-malarial agents (BRIELMANN et 
al., 2006). 
 
6.1.2 Application of Thin Layer Chromatography (TLC) for chemical profiling 
 
Thin layer chromatography (TLC) is a solid-liquid form of chromatography where the 
stationary phase is normally a polar absorbent and the mobile phase can be a single 
solvent or combination of solvents (WAGNER et al., 1984). It is a quick, inexpensive 
micro-scale technique that can be used to analyse and compare the components 
present in mixtures such as plant extracts and drugs. The chemical composition of a 
mixture can be identified when compared with a known standard compound. In 
addition, the resultant chemical profiles can be visualized under ultra-violet radiation 
where the displayed migration distances as well as intensities of characteristic zones 
can be use for identification of possible compounds in the mixture. 
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6.2 Materials and methods 
 
Plant material was collected as described in Section 2.2.1. Due to the high diversity 
in chemical composition of secondary metabolites, different methods of extraction 
and assays were employed to determine the metabolites. To prevent deterioration 
and decomposition of the metabolites, fresh extracts were used for each assay. 
 
6.2.1 Extract preparation 
 
Phenolic compounds were extracted from dry plant material as described by 
MAKKAR (2000). Ground plant materials (2 g) were extracted with 20 ml of 50% 
aqueous methanol (MeOH) by sonicating in water for 20 min. Extracts were filtered 
in vacuo through Whatman No.1 filter paper and used in the assays outlined below. 
 
For TLC chemical profiling, 1 g of the ground plant material was extracted in 10 ml 
acetone in a sonication bath for 30 min. The extracts were filtered in vacuo through 
Whatman No.1 filter paper and air-dried under a stream of cold air. Acetone extract 
compounds across a wide polarity range from plant material (ELOFF, 1998b). 
 
6.2.2  Folin-Ciocalteu assay for total phenolics 
 
The Folin-Ciocalteu (Folin-C) assay, using gallic acid as a standard, was employed 
for the evaluation of total phenolics (MAKKAR, 2000). Folin-C phenol reagent (2N) 
(Sigma-Aldrich, Germany) was made up with an equal volume of distilled water in a 
dark bottle, to obtain a 1N Folin-C reagent required for the assay. Gallic acid   
(Sigma-Aldrich, USA) was prepared in water at 0.1 mg/ml standard solution. In 
triplicate, 50 µl of MeOH extracts were added to 950 µl distilled water in glass test 
tubes, followed by 500 µl Folin-C reagent (1 N) and 2.5 ml sodium carbonate (2%). 
Similarly, a blank that contained 50% aqueous MeOH (50 µl) in place of the extract 
was also prepared. The test mixtures were incubated for 40 min at room temperature 
and the absorbance at 725 nm was measured using a UV-visible spectrophotometer 
(Varian Cary 50, Australia). A standard curve was used to convert the measured 
absorbance readings to total phenolic concentration, expressed as gallic acid 
equivalents (GAE) per gram dry matter. 
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6.2.3  Rhodanine assay for gallotannins 
 
Gallotannin content was determined using the rhodanine assay as described by 
MAKKAR (2000). The reagent rhodanine (Fluka, Germany) was prepared in 
methanol, and gallic acid (0.1 mg/ml) prepared in 0.2 N sulphuric acid was used as 
the standard solution. In triplicate, 50 µl of extracts were added to 950 µl distilled 
water in glass test tubes, followed by the addition of 100 µl sulphuric acid (0.4 N) and 
600 µl rhodanine. After 5 min at room temperature, 200 µl potassium hydroxide  
(0.5 N) was added to the reaction mixture. The mixture was further incubated for  
2½ min at room temperature after which 4 ml distilled water was added. The reaction 
mixture was incubated a further 15 min at room temperature. The blank contained 
water in place of 50 µl extract. Absorbance was measured at 520 nm using a  
UV-visible spectrophotometer. The gallotannin contents in the extracts were 
expressed as gallic acid equivalents (GAE) per gram dry matter. 
 
6.2.4  Butanol-HCl assay for condensed tannins 
 
The condensed tannin content was evaluated using the butanol-HCl assay as 
described by MAKKAR (2000) and modified by NDHLALA et al. (2007). In triplicate, 
3 ml of butanol-HCl reagent (95:5 v/v) was added to 500 µl of each extract, followed 
by 100 µl of ferric reagent (2% ferric ammonium sulphate in 2 N HCl). The reaction 
mixture was thoroughly mixed using a vortex and incubated in a water bath for 1 h at 
100 ºC. A blank test containing 500 µl extract, 3 ml butanol-HCl reagent and 100 µl 
ferric reagent was prepared for each extract, but without heating. After the incubation 
period, absorbance at 550 nm was measured using a UV-visible spectrophotometer 
against each extract blank. Condensed tannin contents (percentage of dry matter) 
were evaluated and expressed as leucocyanidin equivalents (LCE) using the formula 
developed by PORTER et al. (1985): 
 
Condensed tannin (%) = ( A550 × 78.26 × dilution factor) (% yield) , 
 
where A550 = absorbance of sample at 550 nm, 78.26 = molecular weight of 
leucocyanidin, dilution factor = 1 (if no water was added) or = 500 µl/volume of water 
added (when water was added). 
Water was added to prevent the absorbance from exceeding 0.6. 
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6.2.5  Vanillin assay for flavonoids 
 
The flavonoid content was evaluated as described by HANGERMAN (2002) with 
modifications. In triplicate, 50 µl of each extract were diluted with 950 µl of glacial 
acetic acid, followed by the addition of 2.5 ml of 4% HCl in methanol (v/v) and 2.5 ml 
vanillin reagent (4% vanillin in glacial acetic acid, w/v), after which the reaction 
mixture was incubated for 20 min at room temperature. The presence of flavonoids 
was indicated by a pink colouration. After the incubation period, absorbance at  
500 nm was measured using a UV-visible spectrophotometer against a blank 
consisting of water instead of the extract. Flavonoid content was expressed as 
catechin equivalents (CTE) per gram dry matter. 
 
6.2.6  Saponin determination 
 
In duplicate, 5 ml distilled water were added to 0.1 g of ground plant material in test 
tubes. The test tubes were corked and vigorously shaken for 2 min. The appearance 
of a stable foam or froth on the liquid surface after 45 min indicated the presence of 
saponins. The presence of saponins was further confirmed by taking 2 ml of the 
aqueous extract of each sample into a test tube, followed by the addition of olive oil 
(10 drops). The test tube was corked and vigorously shaken. The formation of an 
emulsion confirmed the presence of saponins (TADHANI and SUBHASH, 2006). 
 
6.2.7 Alkaloid determination 
 
From the 50% methanol extracts, 5 ml were transferred to a glass test tube and a 
few drops of ammonium solution were added. The mixture was shaken and 
examined for formation of a precipitate after approximately 2 min (MAKKAR and 
GOODCHILD, 1996). 
 
6.2.8 Thin Layer Chromatography (TLC) chemical profiling 
 
The acetone extracts were redissolved at 50 mg/ml, and 10 µl of each were loaded 
on a TLC plate (5 x 20 cm, Silica gel 60 F254) (Merck, Germany). The plates were 
developed using chloroform:ethyl acetate:formic acid (CEF) (20:16:4 v/v/v). After 
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developing the chemical profiles over a distance of 7.5 cm (solvent front), the TLC 
plates were dried and visualized under ultraviolet light (254 and 366 nm) and 
photographs of the plates were taken to compare the chemical profiles of the various 
extracts. The TLC plates were sprayed with anisaldehyde reagent (Appendix 4) and 
incubated at 110 ºC for approximately 5 min. Thereafter the plates were visualized 
and photographed using a digital camera. 
 
6.3 Results and discussion 
 
The total phenolic content, including tannins and flavonoids were quantitatively 
analysed while qualitative tests were used to indicate the presence of saponins and 
alkaloids in the plant species investigated. 
 
6.3.1 Total phenolic content 
 
The assay was based on the oxidation-reduction principle using the Folin-C reagent. 
This method provides a simple test for determination of total phenolic content of 
plants due to its high sensitivity and reproducibility (MAKKAR et al., 2007). The total 
phenolic content (mg GAE/g dry matter) of the investigated plant extracts are 
presented in Figure 6.1. All the plants had varying concentrations of phenolic 
compounds in the extracts of the different plant parts. The largest amount (56.70 mg 
GAE/g dry matter) of total phenolics was found in O. basilium leaves while the lowest 
quantity (1.70 mg GAE/g dry matter) was found in leaves of C. orbiculata var. 
dactylopsis. Although all the plants investigated contained phenolics, it was observed 
that plants such as Hypoxis species, L. sericea and O. basilicum, that had phenolic 
concentrations above 25 mg GAE/g dry matter, exhibited the most interesting 
pharmacological activities (anthelmintic, antimicrobial and COX inhibition) in this 
study. For instance, H. colchicifolia had the best anthelmintic activity against   
C. elegans. The PE and DCM extracts of L. sericea exhibited the best antibacterial 
activity while O. basilicum displayed a high COX-1 and -2 percentage inhibition. This 
possibly suggests that the quality of the phenolic compounds also plays a major role 













































































































Figure 6.1: Total phenolic content determined using the Folin-C assay, of South 
African plants used as anthelmintics. 
A.o. L - Acokanthera oppositifolia (leaves), A.o. T - A. oppositifolia (twigs), C.m. L - Clerodendrum 
myricoides (leaves), C.m. S - C. myricoides (stems), C.o. L - Cotyledon orbiculata var. orbiculata 
(leaves), C.o. S - C. orbiculata var. orbiculata (stems), C.o.*  L - C. orbiculata var. dactylopsis 
(leaves), C.o.* S - C. orbiculata var. dactylopsis (stems), C.d. L - Cyathea dregei (leaves),  
C.d. R - C. dregei (roots), F.e. L - Felicia erigeroides (leaves), F.e. S - F. erigeroides (stems),  
H.c. L - Hypoxis colchicifolia (leaves), H.c. C - H. colchicifolia (corms), H.h. L - H. hemerocallidea 
(leaves), H.h. C - H. hemerocallidea (corms), L.s. L - Leucosidea sericea (leaves), L.s. S - L. sericea 
(stems), O.b. L - Ocimum basilicum (leaves), S.p. L - Senna petersiana (leaves). 
 
6.3.2 Gallotannin content 
 
The rhodanine assay is based on the hydrolysis of gallotannins to form gallic acid 
which reacts with the rhodanine to give an intense pink colour which is subsequently 
measured spectrophotometrically (MAKKAR et al., 2007). The amount of 
gallotannins determined in the plant materials are shown in Figure 6.2. The 
gallotannin concentration ranged from 45.36 µg GAE/g dry matter determined in   
O. basilicum (leaves) to 1.36 µg GAE/g dry matter in C. orbiculata var. dactylopsis 
(leaves). Due to their chemical differences, gallotannin has been shown to have a 
lower anti-nutritive effect than condensed tannins in ruminants (ROCHFORT et al., 
2008). As a result, hydrolysable tannin containing plants are preferred to those 
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containing condensed tannins. Gallotannins have been reported to possess 
biological activities such as anti-inflammatory, anticancer, antimicrobial and 
antioxidant activities (ERDÈLYI et al., 2005). In this study, most of the plant extracts 
that displayed interesting pharmacological properties also contained a substantial 
concentration of gallotannins. For instance, organic solvent extracts of O. basilicum 
leaves had noteworthy antibacterial activity as well as a high COX percentage 
inhibition. The presence of high amounts of gallotannin could have contributed to this 









































































































Figure 6.2: Gallotannin content determined using the rhodanine assay, of South 
African plants used as anthelmintics. 
A.o. L - Acokanthera oppositifolia (leaves), A.o. T - A. oppositifolia (twigs), C.m. L - Clerodendrum 
myricoides (leaves), C.m. S - C. myricoides (stems), C.o. L - Cotyledon orbiculata var. orbiculata 
(leaves), C.o. S - C. orbiculata var. orbiculata (stems), C.o.*  L - C. orbiculata var. dactylopsis 
(leaves), C.o.* S - C. orbiculata var. dactylopsis (stems), C.d. L - Cyathea dregei (leaves),  
C.d. R - C. dregei (roots), F.e. L - Felicia erigeroides (leaves), F.e. S - F. erigeroides (stems),  
H.c. L - Hypoxis colchicifolia (leaves), H.c. C - H. colchicifolia (corms), H.h. L - H. hemerocallidea 
(leaves), H.h. C - H. hemerocallidea (corms), L.s. L - Leucosidea sericea (leaves), L.s. S - L. sericea 





6.3.3 Condensed tannin content 
 
The butanol-HCl assay is based on the oxidative cleavage of interflavan bonds of 
condensed tannins in the presence of mineral acids in alcoholic solution at 
approximately 100 ºC. This results in the production of pink-coloured anthocyanidins 
which are subsequently measured spectrophotometrically (MAKKAR et al., 2007). 
The condensed tannin (percentage LCE/g dry matter) in the 50% aqueous MeOH 


































































































Figure 6.3: Condensed tannin content determined using the butanol-HCl assay, of 
South African plants used as anthelmintics. 
A.o. L - Acokanthera oppositifolia (leaves), A.o. T - A. oppositifolia (twigs), C.m. L - Clerodendrum 
myricoides (leaves), C.m. S - C. myricoides (stems), C.o. L - Cotyledon orbiculata var. orbiculata 
(leaves), C.o. S - C. orbiculata var. orbiculata (stems), C.o.*  L - C. orbiculata var. dactylopsis 
(leaves), C.o.* S - C. orbiculata var. dactylopsis (stems), C.d. L - Cyathea dregei (leaves),  
C.d. R - C. dregei (roots), F.e. L - Felicia erigeroides (leaves), F.e. S - F. erigeroides (stems),  
H.c. L - Hypoxis colchicifolia (leaves), H.c. C - H. colchicifolia (corms), H.h. L - H. hemerocallidea 
(leaves), H.h. C - H. hemerocallidea (corms), L.s. L - Leucosidea sericea (leaves), L.s. S - L. sericea 
(stems), O.b. L - Ocimum basilicum (leaves), S.p. L - Senna petersiana (leaves). 
 
Apart from C. orbiculata var. dactylopsis leaves and F. erigeroides stems, all the 
plant extracts had varying amounts of condensed tannins. The condensed tannin 
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ranged from 0.009% LCE/g dry matter in C. orbiculata var. orbiculata leaf extract to 
0.4856% LCE/g dry matter in C. myricoides leaf extract. Condensed tannins have 
the ability to denature protein and as the cuticles of nematode larvae are rich in 
glycoprotein, THOMPSON and GEARY (1995) postulated that this ability might be 
responsible for the death of nematodes when incubated with extracts rich in 
condensed tannins. Although, an extract showing noteworthy pharmacological 
activity involves interaction of various compounds, the presence of condensed 
tannins in most of the plants investigated probably contributed to the observed 
interesting anthelmintic activity. Other studies have also showed that condensed 
tannins account for anthelmintic activity in medicinal plants (JACKSON and 
MILLER, 2006; ATHANASIADOU et al., 2007). 
 
6.3.4 Flavonoid content 
 
The flavonoid concentration in the 50% aqueous MeOH extracts of the investigated 
plants are presented in Figure 6.4. All the extracts contained flavonoids at varying 
concentrations. This was especially evident for the different plant parts, as well as 
among the plant species. The leaf extract of L. sericea had the highest flavonoid 
concentration of 0.654 µg CTE/g dry matter while the lowest flavonoid concentration 
of 0.008 µg CTE/g dry matter was found in the leaves of C. orbiculata var. orbiculata.  
 
Several flavonoids have been identified as potential inhibitors of COX and LOX 
enzymes in inflammatory processes (POLYA, 2003; HIRATA et al., 2005). Besides 
A. oppositifolia and Cotyledon species, all the plants that exhibited high to moderate 
inhibitory activity against COX enzymes also had flavonoid concentrations of 
approximately 0.1 mg CTE/g dry matter (see Table 5.1 and 5.2). The flavonoid 
content in these plants probably contributed to their observed interesting COX 
enzyme inhibitory activity. In addition, different classes of flavonoids have also been 
reported to possess other pharmacological activities such as antimicrobial and anti-












































































































Figure 6.4: Flavonoid content determined using the vanillin assay, of South African 
plants used as anthelmintics. 
A.o. L - Acokanthera oppositifolia (leaves), A.o. T - A. oppositifolia (twigs), C.m. L - Clerodendrum 
myricoides (leaves), C.m. S - C. myricoides (stems), C.o. L - Cotyledon orbiculata var. orbiculata 
(leaves), C.o. S - C. orbiculata var. orbiculata (stems), C.o.*  L - C. orbiculata var. dactylopsis 
(leaves), C.o.* S - C. orbiculata var. dactylopsis (stems), C.d. L - Cyathea dregei (leaves),  
C.d. R - C. dregei (roots), F.e. L - Felicia erigeroides (leaves), F.e. S - F. erigeroides (stems),  
H.c. L - Hypoxis colchicifolia (leaves), H.c. C - H. colchicifolia (corms), H.h. L - H. hemerocallidea 
(leaves), H.h. C - H. hemerocallidea (corms), L.s. L - Leucosidea sericea (leaves), L.s. S - L. sericea 
(stems), O.b. L - Ocimum basilicum (leaves), S.p. L - Senna petersiana (leaves). 
.
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6.3.5 Detection of saponins 
 
The presence of saponins in the plants investigated is presented in Table 6.1. The 
amount of foams formed varied from 0.5 to 2 cm and remained stable for 
approximately 45 min. Saponins dissolve in water to form colloidal solutions that 
foam upon vigorous shaking (FRANCIS et al., 2002). Saponins were detected in all 
plant species with the exception of Cotyledon species, O. basilicum and  
S. petersiana. Pharmacological activities such as anti-inflammatory, antimicrobial 
and molluscicidal as well as anti-parasitic activity in many medicinal plant species 
has been attributed to the presence of saponins (SPARG et al., 2004). The 
presence of saponins in the plant extracts could have contributed to the observed 
pharmacological activity of the plants investigated. 
 
6.3.6 Detection of alkaloids 
 
The detection of alkaloids in the plant material investigated is presented in Table 6.1. 
It was indicated as the formation of precipitates in the sample test tubes. Apart from 
leaf extracts of A. oppositifolia, C. orbiculata var. orbiculata, Hypoxis species and    
L. sericea, alkaloids were not detected in the other plant extracts investigated. 
Because the type of alkaloid that may be present in a plant is unknown, it is often 
difficult to detect alkaloids using a single assay, especially a preliminary qualitative 
test as used in this study. Factors contributing to this difficulty include the wide range 
of solubility, numerous different groups and the highly heterogeneous chemical 
properties of alkaloid compounds (MAKKAR et al., 2007). This could be responsible 
for the low number of plant extracts with alkaloids observed in this study. Although 
angiosperm families are rich in alkaloid bases, the distribution is very uneven and 
many families lack them altogether (REID et al., 2005). For instance, a study on the 
phytochemical composition of four species in the family Asteraceae detected the 
presence of alkaloids in only Arctotis auriculata (SALIE et al., 1996). Likewise,    
F. erigeroides is a member of the family Asteraceae known for high alkaloids, but 




Table 6.1: Presence of saponins and alkaloids in the plant extracts investigated. 
Plant species Plant part Saponins Alkaloids 
Acokanthera oppositifolia Leaves - + 
Twigs + - 
Clerodendrum myricoides Leaves - - 
Stems + - 
Cotyledon orbiculata var. dactylopsis Leaves - - 
Stems - - 
Cotyledon orbiculata var. orbiculata Leaves - + 
Stems - - 
Cyathea dregei Leaves + - 
Roots + - 
Felicia erigeroides Leaves + - 
Stems + - 
Hypoxis colchicifolia Leaves - + 
Corms + - 
Hypoxis hemerocallidea Leaves - + 
Corms + - 
Leucosidea sericea Leaves - + 
Stems + - 
Ocimum basilicum Leaves - - 
Senna petersiana Leaves - - 
 + = detected, - = not detected 
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6.3.7 Thin Layer Chromatography (TLC) chemical profiles  
 
The TLC technique is based on the differential distribution of the plant extract 
constituents between the stationary phase and the mobile phase. The solvent 
system allows the different compounds in the plant extract to move at different rates 
across the stationary phase. The chemical profiles of the plants investigated are 
shown in Figure 6.5 and Figure 6.6. The leaf extracts of the plant material showed 
more bands than the other parts and is an indication of the presence of more 
compounds in the leaf extracts. The chemical profiles of the plants observed after 
spraying with the universal indicator anisaldehyde and incubating at 110 ºC for 5 min 
showed the presence of more compounds than when visualized with UV-radiation 
alone (Figures 6.5 C) and (Figure 6.6 C). Some plant extracts such as    
A. oppositifolia, Cotyledon species (Figure 6.5 A, B, C) as well as L. sericea (Figure 
6.6 A, B, C) had similar compounds in both the leaves and stems/twigs. In the 
pharmacological investigation of these plants, the leaf extracts showed better 
bioactivity than the stem extracts. It is possible that the concentration of these same 
compounds was lower in the stems/twigs, or other factors such as synergism and 
antagonist of other compounds, were responsible for the differences in the plant 
parts pharmacology. 
 
Essential oils are mixtures of many substances, predominantly terpenes and 
phenylpropane derivatives (WAGNER et al., 1984). Essential oils are known for their 
pharmacological activities such as antimicrobial and antioxidant activity 
(REICHLING, 1999; RUNYORO et al., 2010). They appear as dark zones under  
254 nm because they contain at least two conjugated double bonds. After spraying 
with anisaldehyde reagents, components of essential oils give a strong blue, green 
and brown colouration (WAGNER et al., 1984). As a result, essential oils and their 
derivative are likely to be present in many plant species such as C. dregei,  
F. erigeroides, Hypoxis species (Figure 6.5 C) and O. basilicum (Figure 6.6, C). 
This probably accounted for some of the antimicrobial activity that was observed in 





Figure 6.5: TLC profiles of plant extracts visualized under (A) UV λ=254 nm  
(B) UV λ= 366 nm fluorescence and (C) visible light after spraying with anisaldehyde 
universal indicator and heating at 110 ºC for 5 min. TLC solvent system used was: 
Chloroform:ethyl acetate:formic acid (CEF 20:16:4 v/v/v). 
A.o. L - Acokanthera oppositifolia (leaves), A.o. T - A. oppositifolia (twigs), C.m. L - Clerodendrum 
myricoides (leaves), C.m. S - C. myricoides (stems), C.o. L - Cotyledon orbiculata var. orbiculata 
(leaves), C.o. S - C. orbiculata var. orbiculata (stems), C.o.* L - C. orbiculata var. dactylopsis (leaves), 





Figure 6.6: TLC profiles of plant extracts visualized under (A) UV λ=254 nm  
(B) UV λ= 366 nm fluorescence and (C) visible light after spraying with anisaldehyde 
universal indicator and heating at 110 ºC for 5 min. TLC solvent system used was: 
Chloroform:ethyl acetate:formic acid (CEF 20:16:4 v/v/v). 
F.e. L- Felicia erigeroides (leaves), F.e. S - F. erigeroides (stems), H.c. L - Hypoxis colchicifolia 
(leaves), H.c. C - H. colchicifolia (corms), H.h. L - H. hemerocallidea (leaves),  
H.h. C - H. hemerocallidea (corms), L.s. L - Leucosidea sericea (leaves), L.s. S - L. sericea (stems), 




Although many of the plant secondary metabolites investigated were found in more 
than one part of the plant, the leaf extracts showed more complexity as depicted in 
the TLC chemical profiles. The results obtained from the phytochemical screening 
provide preliminary information on some important groups of secondary metabolites 
that are present in the plants investigated. This also suggests the types of bioactive 
compounds that may be responsible for the biological activities exhibited by the plant 
extracts. Further studies to isolate and identify the plant bioactive principles present 


























In South Africa, the use of plants for treatment against diseases has been in 
existence for centuries and constitutes part of the culture of a majority of the people 
(VAN STADEN, 2008). Although the country is endowed with a rich plant biodiversity 
that is used in the traditional medicine, the plants have been generally scientifically 
under-studied for efficacy and safety. Recently, a number of South African medicinal 
plants have been studied for pharmacological properties such as antimicrobial, anti-
cancer and anti-HIV activities. Investigation of anthelmintic activity, however, of most 
of these plants has not received much attention. This neglect calls for more 
research, as helminth infections affect a large proportion of the population (JÄGER, 
2005), especially those living in informal and rural settlements across the country. 
Helminth diseases are common among the poor, who are the major users of 
traditional medicine. As a result, a number of plants are used by traditional healers to 
treat these diseases. An ethnopharmacological approach was used in the present 
study to select 11 South African plants used against helminth infections. The plants 
were investigated for their pharmacological efficacy as well as their phytochemical 
composition. In addition, antimicrobial as well as COX-1 and -2 enzyme inhibitory 
activities of these plants were also investigated, because of the association of 
microbial infections and inflammation with helminthiasis. 
 
7.2 Pharmacological activities 
 
In the anthelmintic screening, many of the plant extracts investigated showed activity 
against C. elegans. From the 80 extracts investigated, 19 and 34 extracts exhibited 
high and moderate anthelmintic activity, respectively. The most noteworthy 
anthelmintic activity (MLC = 0.13 mg/ml) was exhibited by the DCM extract of  
H. colchicifolia leaves. Organic solvent extracts of the leaves of C. myricoides, 
Cotyledon species, L. sericea and O. basilicum also displayed noteworthy 
anthelmintic activity. In this study, the organic solvent extracts showed better 
anthelmintic activity than the water extracts. 
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Helminth infections lead to the lowering of the human body immunity with increased 
susceptibility to pathogenic microorganisms such as bacteria and fungi. As a result, 
the plant extracts were also subjected to antimicrobial (antibacterial and antifungal) 
screening. A number of the plant extracts showed high antimicrobial activity against 
the test microorganisms, especially against S. aureus. C. albicans was less sensitive 
to the plant extracts and only the leaf extracts from H. colchicifolia (PE) and  
O. basilicum (water) exhibiting noteworthy antifungal activity (MIC < 1 mg/ml).  
The non-polar (PE and DCM) extracts from L. sericea leaves exhibited the most 
interesting antibacterial activity (MIC = 0.025 mg/ml) against the Gram-positive 
bacteria tested. Likewise, organic solvent extracts from C. dregei roots,  
F. erigeroides leaves and stems, Hypoxis species leaves, O. basilicum leaves and  
S. petersiana leaves also exhibited noteworthy antibacterial activity (MIC < 1 mg/ml). 
Although the water extract of L. sericea leaves had noteworthy antibacterial activity 
against B. subtilis, the other water extracts generally exhibited poor antibacterial 
activity (MIC > 1 mg/ml). 
 
Inflammation is also often associated with helminth infections. The COX enzymes 
are the most important enzymes involved in this complex inflammatory pathway. The 
ability of a plant extract to inhibit COX enzymes indicates the potential of such an 
extract to act as an anti-inflammatory agent. Although the majority of the organic 
solvent extracts exhibited high COX-1 and -2 inhibition at the highest screening 
concentration (250 µg/ml), the inhibition decreased with reduced extract 
concentration of 125 and 62.5 µg/ml. Both organic solvent and water extracts were 
more effective in inhibiting the COX-1 enzyme than the COX-2 enzyme. As the 
inhibition of COX-2 enzyme is generally associated with fewer side effects 
(BOTTING, 2006), the interesting COX-2 inhibitory activity exhibited by the organic 
solvent (PE, DCM and EtOH) extracts of leaves of F. erigeroides, L. sericea,     







7.3 Phytochemical studies 
 
Chemical compounds found in plants, including secondary metabolites, have various 
functions ranging from defence against herbivores and microorganisms to ecological 
adaptations. Recent studies have reported a direct correlation between some plant 
secondary metabolites and pharmacological activities exhibited (CROZIER et al., 
2006). As a result, the phytochemical composition of the plants was investigated so 
as to have an idea of possible secondary metabolites responsible for the observed 
pharmacological activity. Although present in varying amounts, phenolics, including 
gallotannin and flavonoids, were present in all the plants investigated. Higher 
amounts of these compounds were found in the 50% aqueous MeOH extracts from 
Hypoxis species (leaves and corms), L. sericea (leaves and stems), O. basilicum 
(leaves) and S. petersiana (leaves). The plant extracts, as well as C. myricoides 
(leaves) and C. dregei (leaves and roots) extracts, also had a higher concentration of 
condensed tannins while C. orbiculata var. dactylopsis leaf and F. erigeroides stem 
extracts yielded no condensed tannins. Compared to phenolics, saponins and 
alkaloids were qualitatively tested and were relatively scarce in the plant extracts. 
The presence of these secondary metabolites in the plants investigated probably 
contributed to the observed pharmacological activities. TLC plates showing the 
chemical fingerprints of the acetone extracts of the plants investigated also revealed 
some similarities between extracts of the different plant parts as well as among the 
plant species. 
 
7.4 Conclusion and recommendations 
 
In vitro screening is important in validating the traditional use of medicinal plants and 
for providing leads in the search for new active principles. Although noteworthy 
pharmacological activity identified by an in vitro test does not directly confirm that a 
plant extract is an effective medicine, or a suitable candidate for drug development, it 
does provide a basic understanding of the efficacy of a medicinal plant in traditional 
medicine and its potential use as a source of novel chemotherapy. Furthermore, 
active extracts should be subjected to in vivo investigation as well as the isolation 
and identification of bioactive compounds and toxicity testing to determine their safe 
use as medicines. 
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The anti-parasitic effect of many plants has been attributed to plant secondary 
metabolites which can also have an anti-nutritional effect and further studies will be 
necessary to clearly understand the effect of these metabolites in vivo (JACKSON 
and MILLER, 2006). Any beneficial effect of secondary metabolites should be higher 
than any resultant side effects for it to be of therapeutic value and use against 
helminth infections. 
 
The following recommendations could be considered for future pharmacological 
studies for effective helminth infection control: 
 
 During pharmacological investigation of plant extracts, other biological 
activities related to the disease state for which the medicinal plant is used 
should also be tested. This would eliminate the potential loss of discovery of 
other possible bioactive compounds from plant extracts. 
 It is important to investigate other plant parts and related species for similar 
pharmacological activity to enhance plant conservation. This is especially 
important for endangered medicinal plants and in cases where the 
underground parts are used for medicine or plant species are over-harvested 
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Nematode Growth (NG) agar 
NaCl 3 g 
peptone 2.5 g 
agar 17 g 
     
After autoclaving 
1 ml cholesterol in ethanol (5 mg/ml) 
1 ml 1M CaCl2 
1 ml 1M MgSO4 
25 ml potassium phosphate buffer (pH 6.0) 
 
Potassium phosphate buffer (pH 6.0) 
KH2PO4 12.014 g 
K2HPO4 2.807 g 
 
M9 buffer 
Na2HPO4 6 g 
KH2PO4 3 g 
NaCl 5 g 










dissolved in 975 ml distilled water 
were added in order 
order 






65%       glycerol v/v 
0.1 M      MgSO4 
0.025 M  Tris pH 8 
 
Make Tris and add MgSO4 (to make 0.1 M) 
Add glycerol to make it up to 65% 
(For 100 ml, make 35 ml Tris/MgSO4 and add 65 ml glycerol) 
Autoclave and store in fridge at 4 ºC 
Keep sterile 
 
Microorganism stock cultures 
Transfer 800 µl of liquid culture to an autoclaved cryovial 
Add 800 µl of 65% glycerol solution, mix gently and tap. 
















TRIS storage buffer (pH 8.0) 
Tris(hydroxymethyl)aminomethane (TRIS) 80 mM 9.7 g 
TWEEN 20 (0.1 %) 1.0 g  
Sodium diethyldithiocarbamate (trihydrate) 300 µM 0.0676 g 
Distilled water 800 ml 
Hydrogen chloride (HCl) Adjust to pH 8.0 
Distilled water Make up to 1000 ml 
 
TRIS buffer (pH 8.0) used in the bioassay 
TRIS  12.1 g 
Distilled water 800 ml 
Hydrogen chloride Adjust to pH 8.0 
Distilled water Make up to 1000 ml 
 
Hematin Stock solution 
Hematin 1.26 mg 
TRIS  96.9 mg 
Distilled water 10 ml 
 
Phosphate buffer (pH 7.4) 
KH2PO4 2.6 g 
K2HPO4.3H20 18.5 g 









Ethanol 465 ml 
Glacial acetic acid 5 ml 
Sulphuric acid (concentrated) 13 ml 
p-anisaldehyde 13 ml 
 
Cold ethanol measured into a Schott bottle and placed on ice 
 
In above order, other solvents were added and maintained under cold conditions 
 
The prepared anisaldehyde reagent was kept in a freezer after use 
